Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Article category

Page Path
HOME > Article category > Article category
148 Article category
Filter
Filter
Article type
Article category
Keywords
Publication year
Authors
Funded articles
Review Article
Diabetes, Obesity and Metabolism
Effects of Intermittent Fasting on the Circulating Levels and Circadian Rhythms of Hormones
Bo Hye Kim, Yena Joo, Min-Seon Kim, Han Kyoung Choe, Qingchun Tong, Obin Kwon
Endocrinol Metab. 2021;36(4):745-756.   Published online August 27, 2021
DOI: https://doi.org/10.3803/EnM.2021.405
  • 58,991 View
  • 1,283 Download
  • 42 Web of Science
  • 44 Crossref
AbstractAbstract PDFPubReader   ePub   
Intermittent fasting has become an increasingly popular strategy in losing weight and associated reduction in obesity-related medical complications. Overwhelming studies support metabolic improvements from intermittent fasting in blood glucose levels, cardiac and brain function, and other health benefits, in addition to weight loss. However, concerns have also been raised on side effects including muscle loss, ketosis, and electrolyte imbalance. Of particular concern, the effect of intermittent fasting on hormonal circadian rhythms has received little attention. Given the known importance of circadian hormonal changes to normal physiology, potential detrimental effects by dysregulation of hormonal changes deserve careful discussions. In this review, we describe the changes in circadian rhythms of hormones caused by intermittent fasting. We covered major hormones commonly pathophysiologically involved in clinical endocrinology, including insulin, thyroid hormones, and glucocorticoids. Given that intermittent fasting could alter both the level and frequency of hormone secretion, decisions on practicing intermittent fasting should take more considerations on potential detrimental consequences versus beneficial effects pertaining to individual health conditions.

Citations

Citations to this article as recorded by  
  • Intermittent fasting as a dietary intervention with potential sexually dimorphic health benefits
    Julia Rius-Bonet, Salvador Macip, Daniel Closa, Marta Massip-Salcedo
    Nutrition Reviews.2025; 83(2): e635.     CrossRef
  • Intermittent fasting triggers interorgan communication to suppress hair follicle regeneration
    Han Chen, Chao Liu, Shiyao Cui, Yingqian Xia, Ke Zhang, Hanxiao Cheng, Jingyu Peng, Xiaoling Yu, Luyang Li, Hualin Yu, Jufang Zhang, Ju-Sheng Zheng, Bing Zhang
    Cell.2025; 188(1): 157.     CrossRef
  • Common and divergent molecular mechanisms of fasting and ketogenic diets
    Antonio Paoli, Grant M. Tinsley, Mark P. Mattson, Immaculata De Vivo, Ravi Dhawan, Tatiana Moro
    Trends in Endocrinology & Metabolism.2024; 35(2): 125.     CrossRef
  • Identifying Acss1, Mtfp1 and Oxct1 as key regulators and promising biomarkers of sarcopenia in various models
    Hailong Cui, Die Hu, Yanling Liu, Jiejie Zhao
    Gene.2024; 896: 148053.     CrossRef
  • Circadian Rhythms, Chrononutrition, Physical Training, and Redox Homeostasis—Molecular Mechanisms in Human Health
    Cristina Manuela Drăgoi, Alina Crenguţa Nicolae, Anca Ungurianu, Denisa Marilena Margină, Daniela Grădinaru, Ion-Bogdan Dumitrescu
    Cells.2024; 13(2): 138.     CrossRef
  • Various types of fasting diet and possible benefits in nonalcoholic fatty liver: Mechanism of actions and literature update
    Zahra Sadat Mirrazavi, Vahideh Behrouz
    Clinical Nutrition.2024; 43(2): 519.     CrossRef
  • Attention to Innate Circadian Rhythm and the Impact of Its Disruption on Diabetes
    Da Young Lee, Inha Jung, So Young Park, Ji Hee Yu, Ji A Seo, Kyeong Jin Kim, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Nan Hee Kim
    Diabetes & Metabolism Journal.2024; 48(1): 37.     CrossRef
  • Genetics of Exercise and Diet-Induced Fat Loss Efficiency: A Systematic Review
    Aleksandra Bojarczuk, Emiliya S. Egorova, Magdalena Dzitkowska-Zabielska, Ildus I. Ahmetov
    Journal of Sports Science and Medicine.2024; : 236.     CrossRef
  • Ramadan fasting in the third trimester of pregnancy and postpartum colostrum cortisol concentrations in Morocco
    Meagan M. Guilfoyle
    American Journal of Human Biology.2024;[Epub]     CrossRef
  • Dietary factors in circadian rhythm modulation and their impact on metabolic diseases: a state of the science review
    Malvika Dalvi, Srujana Medithi
    Biological Rhythm Research.2024; 55(3-4): 233.     CrossRef
  • Unlocking the Benefits of Fasting: A Review of its Impact on Various Biological Systems and Human Health
    Rawan Mackieh, Nadia Al-Bakkar, Milena Kfoury, Nathalie Okdeh, Hervé Pietra, Rabih Roufayel, Christian Legros, Ziad Fajloun, Jean-Marc Sabatier
    Current Medicinal Chemistry.2024; 31(14): 1781.     CrossRef
  • Chrono-Endocrinology in Clinical Practice: A Journey from Pathophysiological to Therapeutic Aspects
    Silvia Mercadante, Antonio Bellastella
    Life.2024; 14(5): 546.     CrossRef
  • Pu‐erh tea reduces the transmission of CRD‐mediated alopecia risk to offspring
    Shanshan Hu, Jie Wang, Zhiyuan Lin, Bowen Zhang, Liyong Luo, Liang Zeng
    Food Frontiers.2024; 5(4): 1673.     CrossRef
  • Effects of Early and Late Time-Restricted Feeding on Parameters of Metabolic Health: An Explorative Literature Assessment
    Froso Petridi, Jan M. W. Geurts, Jean Nyakayiru, Anne Schaafsma, Dedmer Schaafsma, Ruth C. R. Meex, Cécile M. Singh-Povel
    Nutrients.2024; 16(11): 1721.     CrossRef
  • Ramadan intermittent fasting is associated with improved anticoagulant activity among healthy people: a case–control study
    Abeer Khalid Al-Ghumlas
    Scientific Reports.2024;[Epub]     CrossRef
  • Adaptive Effects of Endocrine Hormones on Metabolism of Macronutrients during Fasting and Starvation: A Scoping Review
    Reza Karimi, Alina Yanovich, Fawzy Elbarbry, Anita Cleven
    Metabolites.2024; 14(6): 336.     CrossRef
  • The effect of intermittent fasting on preventing obesity-related early aging from a molecular and cellular perspective
    Nurma Yuliyanasari, Purwo Sri Rejeki, Hanik Badriyah Hidayati, Phawinee Subsomwong, Muhammad Miftahussurur
    Journal of Medicine and Life.2024; 17(3): 261.     CrossRef
  • Marital Status and Serum Level of Testosterone: In Relation to Serum Level of Cortisol
    Rezanezhad Babak, Borgquist Rasmus, Elzanaty Saad
    Archive of Urological Research.2024; 8(2): 018.     CrossRef
  • Evaluating the efficacy of intermittent fasting and exercise combinations for weight loss: A network meta‐analysis
    Xiaoyan Cheng, Shunli Sun, Maolin Chen, Xinyou Zhou, Mingxin Rao, Dongjuan Guo, Jinfeng Xie, Qiang Huang, Liqiang Su
    Obesity Reviews.2024;[Epub]     CrossRef
  • Effects of Intermittent Fasting on Female Reproductive Function: A Review of Animal and Human Studies
    Lei Mao, Aixia Liu, Xiaohui Zhang
    Current Nutrition Reports.2024; 13(4): 786.     CrossRef
  • Impact of Modern Lifestyle on Circadian Health and Its Contribution to Adipogenesis and Cancer Risk
    Oxana Dobrovinskaya, Javier Alamilla, Miguel Olivas-Aguirre
    Cancers.2024; 16(21): 3706.     CrossRef
  • Religious intermittent fasting: Effects on liver health, metabolic markers, and gut microbiota in type 2 diabetes patients
    Svenja Sydor, Ender Engin, Samantha Wittek, Peter Lemmer, Jan Best, Martin Steinmetz, Anja Figge, Andreas Jähnert, Mustafa Özcürümez, Martina Broecker-Preuss, Wing-Kin Syn, Ali Canbay, Paul Manka
    Clinical Nutrition Open Science.2024; 58: 370.     CrossRef
  • Intermittent fasting: Effectiveness and safety. A review
    Marina V. Altashina, Ekaterina V. Ivannikova, Ekaterina A. Troshina
    Terapevticheskii arkhiv.2024; 96(10): 984.     CrossRef
  • Examining Associations Between Fasting Behavior, Orthorexia Nervosa, and Eating Disorders
    Przemysław Domaszewski, Aleksandra M. Rogowska, Kaja Żylak
    Nutrients.2024; 16(24): 4275.     CrossRef
  • Fasting intervention and its clinical effects on the human host and microbiome
    Sofia K. Forslund
    Journal of Internal Medicine.2023; 293(2): 166.     CrossRef
  • Umbrella review of time-restricted eating on weight loss, fasting blood glucose, and lipid profile
    Han Shi Jocelyn Chew, Wei How Darryl Ang, Zhen Yang Abel Tan, Wen Wei Ang, Kin Sun Chan, Ying Lau
    Nutrition Reviews.2023; 81(9): 1180.     CrossRef
  • Thermodynamic Assessment of the Effects of Intermittent Fasting and Fatty Liver Disease Diets on Longevity
    Melek Ece Öngel, Cennet Yildiz, Özge Başer, Bayram Yilmaz, Mustafa Özilgen
    Entropy.2023; 25(2): 227.     CrossRef
  • Effects of Intermittent Fasting on Hypothalamus–Pituitary–Thyroid Axis, Palatable Food Intake, and Body Weight in Stressed Rats
    Cinthia García-Luna, Ixchel Prieto, Paulina Soberanes-Chávez, Elena Alvarez-Salas, Iván Torre-Villalvazo, Gilberto Matamoros-Trejo, Patricia de Gortari
    Nutrients.2023; 15(5): 1164.     CrossRef
  • Possible homeostatic, glucose uptake mechanisms and hepato-pancreatic histological effects of intermittent fasting, exercise, starvation, and honey in streptozotocin-induced diabetes in rats
    Ejime A. Chijiokwu, Eze K. Nwangwa, Mega O. Oyovwi, Benneth Ben-Azu, Alexander O. Naiho, Emuesiri Goodies Moke, Victor Emojevwe, Prosper A. Ehiwarior, Udoka S. Nwabuoku
    Nutrire.2023;[Epub]     CrossRef
  • Mid-Point of the Active Phase Is Better to Achieve the Natriuretic Effect of Acute Salt Load in Mice
    Momoko Imamura, Hiroyuki Sasaki, Katsuki Hayashi, Shigenobu Shibata
    Nutrients.2023; 15(7): 1679.     CrossRef
  • All That Glitters Is Not Gold: The Same Sleep Time, but Different Diabetogenic Outcomes
    Bohye Kim, Obin Kwon
    Endocrinology and Metabolism.2023; 38(1): 78.     CrossRef
  • The emerging role of circadian rhythms in the development and function of thermogenic fat
    Xuemin Peng, Yong Chen
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Time-restricted Feeding Changes as Inspiration for Drug Design
    Zhangyuting He, Huayu Yang, Yilei Mao
    Current Pharmaceutical Design.2023; 29(8): 559.     CrossRef
  • Brain Dopamine–Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects
    Anthony H. Cincotta
    International Journal of Molecular Sciences.2023; 24(17): 13255.     CrossRef
  • Adaptive Circadian Rhythms for Autonomous and Biologically Inspired Robot Behavior
    Marcos Maroto-Gómez, María Malfaz, Álvaro Castro-González, Sara Carrasco-Martínez, Miguel Ángel Salichs
    Biomimetics.2023; 8(5): 413.     CrossRef
  • Intermittent Fasting on Human Health and Disease
    Denisa Marilena Margină, Cristina Manuela Drăgoi
    Nutrients.2023; 15(21): 4491.     CrossRef
  • Synthetic augmentation of bilirubin metabolism in human pluripotent stem cell-derived liver organoids
    Hasan Al Reza, Zishaan Farooqui, Abid Al Reza, Callen Conroy, Kentaro Iwasawa, Yasuhiro Ogura, Keisuke Okita, Kenji Osafune, Takanori Takebe
    Stem Cell Reports.2023; 18(11): 2071.     CrossRef
  • Average phenotype but not plasticity in two metabolic hormones covary in wild female bonobos (Pan paniscus)
    Ruth Sonnweber, Gottfried Hohmann, Jeroen M. G. Stevens, Tobias Deschner, Barbara Fruth, Anna-Lena Fiedler, Niina O. Nurmi, Verena Behringer
    Frontiers in Ecology and Evolution.2023;[Epub]     CrossRef
  • Intermittent fasting, high-intensity interval training, or a combination of both have beneficial effects in obese mice with nonalcoholic fatty liver disease
    Patrícia de Castro-de-Paiva, Thatiany de Souza Marinho, Carlos Alberto Mandarim-de-Lacerda, Marcia Barbosa Aguila
    The Journal of Nutritional Biochemistry.2022; 104: 108997.     CrossRef
  • Optimal Timing of Thyroid Hormone Replacement During Ramadan Fasting: A Randomized Controlled Trial in Patients with Prior Total Thyroidectomy
    Khalid M. Al-Qahtani, Ibraheem Ahmed Aldeeri, Amal M. Alshaibi, Norah Salman Alshabib, Rakan M. Barghouthi, Ebtihal Y. Alyusuf, Anwar Ali Jammah
    Thyroid.2022; 32(9): 1029.     CrossRef
  • Exploring the Effects of Energy Constraints on Performance, Body Composition, Endocrinological/Hematological Biomarkers, and Immune System among Athletes: An Overview of the Fasting State
    Hadi Nobari, Saber Saedmocheshi, Eugenia Murawska-Ciałowicz, Filipe Manuel Clemente, Katsuhiko Suzuki, Ana Filipa Silva
    Nutrients.2022; 14(15): 3197.     CrossRef
  • Alternate day fasting and time-restricted feeding may confer similar neuroprotective effects during aging in male rats
    Sukanya Bhoumik, Rashmi Kesherwani, Raushan Kumar, Syed Ibrahim Rizvi
    Biogerontology.2022; 23(6): 757.     CrossRef
  • Intermittent Fasting—A Healthy Dietary Pattern for Diabetic Nephropathy
    Ming Yang, Wei Chen, Liyu He, Di Liu, Li Zhao, Xi Wang
    Nutrients.2022; 14(19): 3995.     CrossRef
  • β-hydroxybutyrate as an Anti-Aging Metabolite
    Lian Wang, Peijie Chen, Weihua Xiao
    Nutrients.2021; 13(10): 3420.     CrossRef
Close layer
Namgok Lecture 2021
Diabetes, Obesity and Metabolism
The Influence of Obesity and Metabolic Health on Vascular Health
Eun-Jung Rhee
Endocrinol Metab. 2022;37(1):1-8.   Published online February 28, 2022
DOI: https://doi.org/10.3803/EnM.2022.101
  • 12,000 View
  • 374 Download
  • 31 Web of Science
  • 38 Crossref
AbstractAbstract PDFPubReader   ePub   
The prevalence of obesity is rapidly increasing worldwide. Obesity should not be understood only as the accumulation of fat in the body, but instead as a phenomenon that exerts different effects on our health according to the place of fat deposition and its stability. Obesity is the starting point of most metabolic diseases, such as diabetes, hypertension, metabolic syndrome, sleep apnea, and eventually cardiovascular disease. There are different kinds of obesity, ranging from simple obesity to sarcopenic obesity. The main purpose of intervening to address obesity is to decrease the ultimate consequence of obesity—namely, cardiovascular disease. The main mechanism through which obesity, especially abdominal obesity, increases cardiovascular risk is the obesity-induced derangement of metabolic health, leading to the development of metabolic diseases such as diabetes, non-alcoholic fatty liver disease, and metabolic syndrome, which are the main initiators of vascular damage. In this review, I discuss the influence of various types of obesity on the risk of metabolic diseases, and how these diseases increase cardiovascular disease risk.

Citations

Citations to this article as recorded by  
  • Fermented soy products: A review of bioactives for health from fermentation to functionality
    Iskandar Azmy Harahap, Joanna Suliburska, Asli Can Karaca, Esra Capanoglu, Tuba Esatbeyoglu
    Comprehensive Reviews in Food Science and Food Safety.2025;[Epub]     CrossRef
  • Ameliorative effects of Asiasarum root and rhizome extract on high fat diet‑induced obesity in mice through regulation of the SIRT1/PGC1α/AMPK pathways in muscle and liver tissues
    Chenzi Lyu, Seok Kang, Haifeng Shao, Dongeun Kim, Hyo Jung
    Molecular Medicine Reports.2025;[Epub]     CrossRef
  • Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study
    Nam Hoon Kim, Ji Yoon Kim, Jimi Choi, Sin Gon Kim
    European Heart Journal - Cardiovascular Pharmacotherapy.2024; 10(2): 118.     CrossRef
  • Severity of abdominal obesity and cardiometabolic diseases in US adults
    S. Wang, S. Shi, Y. Huang, H. Huang, V.W. Zhong
    Public Health.2024; 227: 154.     CrossRef
  • Association between lipid accumulation product and psoriasis among adults: a nationally representative cross-sectional study
    Caiyun Zhang, Xiaoping Dong, Jun Chen, Fang Liu
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Anti-obesity effects of fucoidan from Sargassum thunbergii in adipocytes and high fat diet induced obese mice through inhibiting adipogenic specific transcription factor
    Hyo-Geun Lee, H.H.A.C.K. Jayawardhana, Fengqi Yang, D.P. Nagahawaththa, N.M. Liyanage, Kyung-Mo Song, Yun-Sang Choi, Seung-Hong Lee, You-Jin Jeon, Min-Cheol Kang
    Food Science and Human Wellness.2024; 13(3): 1608.     CrossRef
  • Association of a High Healthy Eating Index Diet with Long-Term Visceral Fat Loss in a Large Longitudinal Study
    Sunmin Park
    Nutrients.2024; 16(4): 534.     CrossRef
  • Ancistrocladus tectorius Extract Inhibits Obesity by Promoting Thermogenesis and Mitochondrial Dynamics in High-Fat Diet-Fed Mice
    Minju Kim, Jin Hyub Paik, Hwa Lee, Min Ji Kim, Sang Mi Eum, Soo Yong Kim, Sangho Choi, Ho-Yong Park, Hye Gwang Jeong, Tae-Sook Jeong
    International Journal of Molecular Sciences.2024; 25(7): 3743.     CrossRef
  • Biological Activity Evaluation of Olive, Grape, and Fig at Various Mixing Ratios
    Chan-Hwi Lee, So-Young Lee, Ae-Jung Kim
    Asian Journal of Beauty and Cosmetology.2024; 22(1): 91.     CrossRef
  • Investigation and Comparison of Maternal Pre-Pregnancy Body Mass Index Coupled with Gestational Weight Gain on Maternal–Fetal Complications Based on US and Chinese Guidelines: A Retrospective Study
    Wan-Ju Kung, Hsin-Yi Kuo, Ching-Feng Chang, Yeong-Hwa Zen, Ching-Chiang Lin
    Reproductive Sciences.2024; 31(8): 2379.     CrossRef
  • Docosahexanoic Acid Attenuates Palmitate-Induced Apoptosis by Autophagy Upregulation via GPR120/mTOR Axis in Insulin-Secreting Cells
    Seok-Woo Hong, Jinmi Lee, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
    Endocrinology and Metabolism.2024; 39(2): 353.     CrossRef
  • Adipokine Modulation in Endometrial Hyperplasia by Polyunsaturated Fatty Acids
    Athuru Supriya, Ammu V. V. V. Ravi Kiran, Praveen Thaggikuppe Krishnamurthy
    Journal of Pharmacology and Pharmacotherapeutics.2024; 15(3): 237.     CrossRef
  • Association of osteoporosis with sarcopenia and its components among community-dwelling older Chinese adults with different obesity levels: A cross-sectional study
    Xing Yu, Yaqing Zheng, Yuewen Liu, Peipei Han, Xiaoyu Chen, Naiwen Zhang, Yejia Ni, Ziyi Zhou, Qi Guo
    Medicine.2024; 103(24): e38396.     CrossRef
  • Association between mixed exposure to per- and polyfluoroalkyl substances and metabolic syndrome in Korean adults: Data from the Korean National environmental health survey cycle 4
    Seung Min Chung, Kyun Hoo Kim, Jun Sung Moon, Kyu Chang Won
    International Journal of Hygiene and Environmental Health.2024; 261: 114427.     CrossRef
  • Advances in the Synthesis and Physiological Metabolic Regulation of Nicotinamide Mononucleotide
    Chuxiong Zheng, Yumeng Li, Xin Wu, Le Gao, Xiaoyi Chen
    Nutrients.2024; 16(14): 2354.     CrossRef
  • Impact of metabolic parameters and risk factors on surfactant proteins SP-A and SP-D in abdominal obesity
    K.Yu. Nikolaev, Ya.K. Lapitskaya, I.A. Kosarev, N.F. Dadashova
    Russian Journal of Preventive Medicine.2024; 27(7): 60.     CrossRef
  • Metabolic health in people living with type 1 diabetes in Belgium: a repeated cross-sectional study
    Astrid Lavens, Christophe De Block, Philippe Oriot, Laurent Crenier, Jean-Christophe Philips, Michel Vandenbroucke, An-Sofie Vanherwegen, Frank Nobels, Chantal Mathieu
    Diabetologia.2024; 67(12): 2678.     CrossRef
  • Association between lipid accumulation products and gallstones: an analysis of the National Health and Nutrition Examination Survey 2017–2020
    Huimin Wang, Xiaojia Feng, Qihui Huang, Xiaowei Zheng
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Lipid accumulation product, poverty income ratio, and bone mineral density in U.S. adults: a mediation analysis based on NHANES (2009–2020)
    Zihao Chen, Haobo Ye, Enli Li, Yuzhe Lin, Chen Jin, Lei Yang
    Frontiers in Nutrition.2024;[Epub]     CrossRef
  • Epidemiology and Trends of Obesity and Bariatric Surgery in Korea
    Kyungdo Han, Jin-Hyung Jung, Su-Min Jeong, Mee Kyoung Kim
    Endocrinology and Metabolism.2024; 39(5): 678.     CrossRef
  • Assessment of Paraoxonase 1 and Arylesterase Activities and Lipid Profile in Bodybuilders: A Comparative Study of Physical Activity and Anthropometry on Atherosclerosis
    Hakim Celik, Mehmed Zahid Tuysuz, Yakup Aktas, Mehmet Ali Eren, Recep Demirbag
    Medicina.2024; 60(10): 1717.     CrossRef
  • Evaluation of Health Associations With Height‐Normalised Abdominal Body Composition Indices: A Single‐Centre Cross‐Sectional Study
    Yupeng Liu, Hangqian He, Keyu Qian, Yufeng Huang, Xuemei Ao, Xudong Shi, Binye Ruan, Ru Xue, Xiaoyi Fu, Shuran Wang
    Journal of Cachexia, Sarcopenia and Muscle.2024; 15(6): 2651.     CrossRef
  • Herbal appetite suppressants used to aid weight loss
    Sonia Malik, Sultana Patel, Dhvani H. Kuntawala, Gael N. N. Neba Ambe, Yannan Jin, Avninder S. Bhambra, Randolph R. J. Arroo
    Phytochemistry Reviews.2024;[Epub]     CrossRef
  • Association between lipid accumulation products and stress urinary incontinence: a cross-sectional study from NHANES 2005 to 2018
    JiHang Li, Dong Wang, Hu Tian, JianKun Yang, Hui Xia, WenBin Guo
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Impact of non-sugar sweeteners on metabolism beyond sweet taste perception
    Herbert Herzog, Lei Zhang, Luigi Fontana, G. Gregory Neely
    Trends in Endocrinology & Metabolism.2024;[Epub]     CrossRef
  • Exploring the relationship between trunk flexibility and arterial stiffness measured by pulse wave velocity: A systematic review and meta-analysis
    Iván Cavero-Redondo, Helder Fonseca, Iris Otero-Luis, Lucimere Bohn, Carla Geovanna Lever-Megina, Nerea Moreno-Herraiz, Alicia Saz-Lara, Sebastian Schnaubelt
    PLOS ONE.2024; 19(12): e0311611.     CrossRef
  • Mechanistic insights into dietary (poly)phenols and vascular dysfunction-related diseases using multi-omics and integrative approaches: Machine learning as a next challenge in nutrition research
    Dragan Milenkovic, Tatjana Ruskovska
    Molecular Aspects of Medicine.2023; 89: 101101.     CrossRef
  • Pharmacological Support for the Treatment of Obesity—Present and Future
    Marcin Kosmalski, Kacper Deska, Bartłomiej Bąk, Monika Różycka-Kosmalska, Tadeusz Pietras
    Healthcare.2023; 11(3): 433.     CrossRef
  • Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes
    Donna H. Ryan, John E. Deanfield, Stephan Jacob
    Cardiovascular Endocrinology & Metabolism.2023; 12(1): e0279.     CrossRef
  • Adipopenia is associated with osteoporosis in community-dwelling non-underweight adults independent of sarcopenia
    Seunghyun Lee, Kyoungmyoung Ko, Sungjae Shin, Hye Sun Park, Namki Hong, Yumie Rhee
    Archives of Osteoporosis.2023;[Epub]     CrossRef
  • Design, synthesis and evaluation of 2-pyrimidinylindole derivatives as anti-obesity agents by regulating lipid metabolism
    Shi-Yao Guo, Li-Yuan Wei, Bing-Bing Song, Yu-Tao Hu, Zhi Jiang, Dan-Dan Zhao, Yao-Hao Xu, Yu-Wei Lin, Shu-Min Xu, Shuo-Bin Chen, Zhi-Shu Huang
    European Journal of Medicinal Chemistry.2023; 260: 115729.     CrossRef
  • Short-Term L-Citrulline Supplementation Does Not Affect Blood Pressure, Pulse Wave Reflection, or Arterial Stiffness at Rest and during Isometric Exercise in Older Males
    Andrea Tryfonos, Filippos Christodoulou, George M. Pamboris, Stephanos Christodoulides, Anastasios A. Theodorou
    Sports.2023; 11(9): 177.     CrossRef
  • Skinfold Thickness as a Cardiometabolic Risk Predictor in Sedentary and Active Adult Populations
    Sughey González-Torres, Luis Miguel Anaya-Esparza, Gabriel Fermín Trigueros del Valle, Edgar Alfonso Rivera-León, Zuamí Villagrán, Sergio Sánchez-Enríquez
    Journal of Personalized Medicine.2023; 13(9): 1326.     CrossRef
  • Impact of COVID-19 Lockdown on Non-Alcoholic Fatty Liver Disease and Insulin Resistance in Adults: A before and after Pandemic Lockdown Longitudinal Study
    Ángel Arturo López-González, Bárbara Altisench Jané, Luis Masmiquel Comas, Sebastiana Arroyo Bote, Hilda María González San Miguel, José Ignacio Ramírez Manent
    Nutrients.2022; 14(14): 2795.     CrossRef
  • Fenofibrate enhances lipid deposition via modulating PPARγ, SREBP-1c, and gut microbiota in ob/ob mice fed a high-fat diet
    Ying Zhang, Xiu-Bin Jia, Yun-Chao Liu, Wen-Qian Yu, Yan-Hong Si, Shou-Dong Guo
    Frontiers in Nutrition.2022;[Epub]     CrossRef
  • Predictive Roles of Basal Metabolic Rate and Body Water Distribution in Sarcopenia and Sarcopenic Obesity: The link to Carbohydrates
    Lizheng Guan, Tiantian Li, Xuan Wang, Kang Yu, Rong Xiao, Yuandi Xi
    Nutrients.2022; 14(19): 3911.     CrossRef
  • Metabolic risk factors in patients with comorbidity in Ufa primary health care
    O.V. Molchanova, A.V. Mamaeva, A.R. Dunayeva, Z.A. Lust, E.M. Faskhetdinova, R.N. Shepel, D.O. Orlov, L.M. Zhamalov, G.F. Andreeva, O.M. Drapkina
    Profilakticheskaya meditsina.2022; 25(9): 39.     CrossRef
  • Assessment of Vitamin D Levels in Relation to Statin Therapy in Elderly Hypertensive Patients with Comorbidities
    Kinga-Ilona Nyulas, Zsuzsánna Simon-Szabó, Zoltán Preg, Sándor Pál, Arundhati Sharma, Tünde Pál, Márta Germán-Salló, Enikő Nemes-Nagy
    Journal of Interdisciplinary Medicine.2022; 7(4): 88.     CrossRef
Close layer
Review Articles
Diabetes, Obesity and Metabolism
Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus
Jin Yu, Seung-Hwan Lee, Mee Kyoung Kim
Endocrinol Metab. 2022;37(1):26-37.   Published online February 28, 2022
DOI: https://doi.org/10.3803/EnM.2022.105
  • 23,313 View
  • 1,346 Download
  • 32 Web of Science
  • 33 Crossref
AbstractAbstract PDFPubReader   ePub   
Guidelines for the management of patients with diabetes have become an important part of clinical practice that improve the quality of care and help establish evidence-based medicine in this field. With rapidly accumulating evidence on various aspects of diabetes care, including landmark clinical trials of treatment agents and newer technologies, timely updates of the guidelines capture the most current state of the field and present a consensus. As a leading academic society, the Korean Diabetes Association publishes practice guidelines biennially and the American Diabetes Association does so annually. In this review, we summarize the key changes suggested in the most recent guidelines. Some of the important updates include treatment algorithms emphasizing comorbid conditions such as atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease in the selection of anti-diabetic agents; wider application of continuous glucose monitoring (CGM), insulin pump technologies and indices derived from CGM such as time in range; more active screening of subjects at high-risk of diabetes; and more detailed individualization in diabetes care. Although there are both similarities and differences among guidelines and some uncertainty remains, these updates provide a good approach for many clinical practitioners who are battling with diabetes.

Citations

Citations to this article as recorded by  
  • Drug origami: A computation-guided approach for customizable drug release kinetics of oral formulations
    Hao Huang, Haoyu Zhang, Ningjie Du, Yidan Lyu, Jiahang Xu, Haoran Fu, Yixin Guan, Kewang Nan
    Matter.2025; 8(1): 101878.     CrossRef
  • Long-term levels of bile acids, fibroblast growth factor-19, and glucagon-like peptide-1 after bariatric surgery
    Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Hyun Baek, Ki-Ho Song
    Asian Journal of Surgery.2025; 48(1): 356.     CrossRef
  • Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors on in-hospital mortality following pneumonia without heart failure: A retrospective cohort study of older adults with diabetes
    Hiroki Maki, Toshiaki Isogai, Nobuaki Michihata, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga
    Respiratory Investigation.2025; 63(1): 88.     CrossRef
  • Glycemia Risk Index is Associated With Risk of Albuminuria Among Individuals With Type 1 Diabetes
    Ji Yoon Kim, Jee Hee Yoo, Nam Hoon Kim, Jae Hyeon Kim
    Journal of Diabetes Science and Technology.2025;[Epub]     CrossRef
  • Finerenone: Efficacy of a New Nonsteroidal Mineralocorticoid Receptor Antagonist in Treatment of Patients With Chronic Kidney Disease and Type 2 Diabetes
    Subo Dey, Jasmine Garg, Andy Wang, Eva Holzner, William H. Frishman, Wilbert S. Aronow
    Cardiology in Review.2024; 32(3): 285.     CrossRef
  • Use of Diabetes Medications before and after a Heart Failure–Related Hospitalization among Nursing Home Residents
    Tingting Zhang, Andrew R. Zullo, Kaleen (Kaley) N. Hayes, Dae Hyun Kim, Yoojin Lee, Lori A. Daiello, Douglas P. Kiel, Sarah D. Berry
    Journal of the American Medical Directors Association.2024; 25(3): 454.     CrossRef
  • Accuracy and Safety of the 15-Day CareSens Air Continuous Glucose Monitoring System
    Kyung-Soo Kim, Seung-Hwan Lee, Won Sang Yoo, Cheol-Young Park
    Diabetes Technology & Therapeutics.2024; 26(4): 222.     CrossRef
  • Body composition and metabolic syndrome in patients with type 1 diabetes
    Qiong Zeng, Xiao-Jing Chen, Yi-Ting He, Ze-Ming Ma, Yi-Xi Wu, Kun Lin
    World Journal of Diabetes.2024; 15(1): 81.     CrossRef
  • The best internal structure of the Diabetes Quality of Life Measure (DQOL) in Brazilian patients
    Denilson Menezes Almeida, Aldair Darlan Santos-de-Araújo, José Mário Costa Brito Júnior, Marcela Cacere, André Pontes-Silva, Cyrene Piazera Costa, Maria Cláudia Gonçalves, José Márcio Soares Leite, Almir Vieira Dibai-Filho, Daniela Bassi-Dibai
    BMC Public Health.2024;[Epub]     CrossRef
  • Diabetes Duration, Cholesterol Levels, and Risk of Cardiovascular Diseases in Individuals With Type 2 Diabetes
    Mee Kyoung Kim, Kyu Na Lee, Kyungdo Han, Seung-Hwan Lee
    The Journal of Clinical Endocrinology & Metabolism.2024; 109(12): e2317.     CrossRef
  • SGLT2 inhibitors and their possible use in prevention and treatment of neurological diseases
    Mateusz Sobczyk, Daria Żuraw, Paulina Oleksa, Kacper Jasiński, Mikołaj Porzak, Michał Dacka
    Prospects in Pharmaceutical Sciences.2024; 22(1): 16.     CrossRef
  • Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial
    Ji Yoon Kim, Sang-Man Jin, Eun Seok Kang, Soo Heon Kwak, Yeoree Yang, Jee Hee Yoo, Jae Hyun Bae, Jun Sung Moon, Chang Hee Jung, Ji Cheol Bae, Sunghwan Suh, Sun Joon Moon, Sun Ok Song, Suk Chon, Jae Hyeon Kim
    Diabetologia.2024; 67(7): 1235.     CrossRef
  • Continuous glucose monitoring data for artificial intelligence-based predictive glycemic event: A potential aspect for diabetic care
    Lim Pei Ying, Oh Xin Yin, Ong Wei Quan, Neha Jain, Jayashree Mayuren, Manisha Pandey, Bapi Gorain, Mayuren Candasamy
    International Journal of Diabetes in Developing Countries.2024;[Epub]     CrossRef
  • Optimizing postprandial glucose prediction through integration of diet and exercise: Leveraging transfer learning with imbalanced patient data
    Shinji Hotta, Mikko Kytö, Saila Koivusalo, Seppo Heinonen, Pekka Marttinen, Everson Nunes
    PLOS ONE.2024; 19(8): e0298506.     CrossRef
  • Diet and gut microbiome: Impact of each factor and mutual interactions on prevention and treatment of type 1, type 2, and gestational diabetes mellitus
    Davide Menafra, Mattia Proganò, Nicola Tecce, Rosario Pivonello, Annamaria Colao
    Human Nutrition & Metabolism.2024; 38: 200286.     CrossRef
  • Real-time continuous glucose monitoring vs. self-monitoring of blood glucose: cost-utility in South Korean type 2 diabetes patients on intensive insulin
    Ji Yoon Kim, Sabrina Ilham, Hamza Alshannaq, Richard F. Pollock, Waqas Ahmed, Gregory J. Norman, Sang-Man Jin, Jae Hyeon Kim
    Journal of Medical Economics.2024; 27(1): 1245.     CrossRef
  • Changes in the Epidemiological Landscape of Diabetes in South Korea: Trends in Prevalence, Incidence, and Healthcare Expenditures
    Kyoung Hwa Ha, Dae Jung Kim
    Endocrinology and Metabolism.2024; 39(5): 669.     CrossRef
  • Utilisation of blood glucose test strips in insulin-requiring people with diabetes mellitus using continuous glucose monitoring in Saxony-Anhalt – Analysis of health insurance data
    Sara Lena Lückmann, Antonia Förster, Stephanie Heinrich, Christian Buhtz, Gabriele Meyer, Rafael Mikolajczyk, Steffen Fleischer
    Diabetes Research and Clinical Practice.2024; 218: 111935.     CrossRef
  • Clinical Profile, Comorbidities and Therapies in Type 2 Diabetes Patients on Sitagliptin-Based Therapy in Indian Outpatient Setting
    Khurshid A Bhat, Kiran P Singh, Hanumantha Rao Maddukuri, S N Routray, Shreya Sharma, Surendra Kumar Sharma, Kamlesh Patel, Veena Kinare, Pradip Mate, R V Lokesh Kumar
    Cureus.2024;[Epub]     CrossRef
  • Glycemic control and associated factors in patients with type 2 diabetes in Southwest Ethiopia: a prospective observational study
    Aster Wakjira Garedo, Gorfineh Teshome Tesfaye, Rahel Tamrat, Evelien Wynendaele
    BMC Endocrine Disorders.2024;[Epub]     CrossRef
  • A nationwide cohort study on diabetes severity and risk of Parkinson disease
    Kyungdo Han, Bongsung Kim, Seung Hwan Lee, Mee Kyoung Kim
    npj Parkinson's Disease.2023;[Epub]     CrossRef
  • Optimal Low-Density Lipoprotein Cholesterol Level for Primary Prevention in Koreans with Type 2 Diabetes Mellitus
    Ji Yoon Kim, Nam Hoon Kim
    Diabetes & Metabolism Journal.2023; 47(1): 42.     CrossRef
  • Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
    Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S
    Diabetes & Metabolism.2023; 49(4): 101440.     CrossRef
  • Impact of mental disorders on the risk of heart failure among Korean patients with diabetes: a cohort study
    Tae Kyung Yoo, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee
    Cardiovascular Diabetology.2023;[Epub]     CrossRef
  • Chronic disease management program applied to type 2 diabetes patients and prevention of diabetic complications: a retrospective cohort study using nationwide data
    Min Kyung Hyun, Jang Won Lee, Seung-Hyun Ko
    BMC Public Health.2023;[Epub]     CrossRef
  • Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key
    Marta Alonso-Peña, Maria Del Barrio, Ana Peleteiro-Vigil, Carolina Jimenez-Gonzalez, Alvaro Santos-Laso, Maria Teresa Arias-Loste, Paula Iruzubieta, Javier Crespo
    International Journal of Molecular Sciences.2023; 24(13): 10718.     CrossRef
  • Association between type 2 diabetes mellitus and depression among Korean midlife women: a cross-sectional analysis study
    You Lee Yang, Eun-Ok Im, Yunmi Kim
    BMC Nursing.2023;[Epub]     CrossRef
  • Access to novel anti-diabetic agents in resource limited settings: A brief commentary
    Poobalan Naidoo, Kiolan Naidoo, Sumanth Karamchand, Rory F Leisegang
    World Journal of Diabetes.2023; 14(7): 939.     CrossRef
  • Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis
    Tirath Patel, Fnu Nageeta, Rohab Sohail, Tooba Shaukat Butt, Shyamala Ganesan, Fnu Madhurita, Muhammad Ahmed, Mahrukh Zafar, Wirda Zafar, Mohammad Uzair Zaman, Giustino Varrassi, Mahima Khatri, Satesh Kumar
    Annals of Medicine.2023;[Epub]     CrossRef
  • Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis
    Sagar Dholariya, Siddhartha Dutta, Ragini Singh, Deepak Parchwani, Amit Sonagra, Mehul Kaliya
    Expert Opinion on Pharmacotherapy.2023; 24(18): 2187.     CrossRef
  • Analysis of the management and therapeutic performance of diabetes mellitus employing special target
    Hong-Yan Sun, Xiao-Yan Lin
    World Journal of Diabetes.2023; 14(12): 1721.     CrossRef
  • Zinc Chloride Enhances the Antioxidant Status, Improving the Functional and Structural Organic Disturbances in Streptozotocin-Induced Diabetes in Rats
    Irina Claudia Anton, Liliana Mititelu-Tartau, Eliza Gratiela Popa, Mihaela Poroch, Vladimir Poroch, Ana-Maria Pelin, Liliana Lacramioara Pavel, Ilie Cristian Drochioi, Gina Eosefina Botnariu
    Medicina.2022; 58(11): 1620.     CrossRef
  • The Effectiveness of Eye Movement Desensitization and Reprocessing Therapy on Death Anxiety and Perceived Stress in Patients with Type 2 Diabetes
    Sh Valizadeh Shafagh, S Taklavi, R Kazemi
    Journal of Health and Care.2022; 24(3): 245.     CrossRef
Close layer
Diabetes, Obesity and Metabolism
Big Data Articles (National Health Insurance Service Database)
Big Data Research in the Field of Endocrine Diseases Using the Korean National Health Information Database
Sun Wook Cho, Jung Hee Kim, Han Seok Choi, Hwa Young Ahn, Mee Kyoung Kim, Eun Jung Rhee
Endocrinol Metab. 2023;38(1):10-24.   Published online February 9, 2023
DOI: https://doi.org/10.3803/EnM.2023.102
  • 6,617 View
  • 298 Download
  • 24 Web of Science
  • 25 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
The Korean National Health Information Database (NHID) contains big data combining information obtained from the National Health Insurance Service and health examinations. Data are provided in the form of a cohort, and the NHID can be used to conduct longitudinal studies and research on rare diseases. Moreover, data on the cause and date of death are provided by Statistics Korea. Research and publications based on the NHID have increased explosively in the field of endocrine disorders. However, because the data were not collected for research purposes, studies using the NHID have limitations, particularly the need for the operational definition of diseases. In this review, we describe the characteristics of the Korean NHID, operational definitions of endocrine diseases used for research, and an overview of recent studies in endocrinology using the Korean NHID.

Citations

Citations to this article as recorded by  
  • Different Associations between Lipid Levels and Risk for Heart Failure according to Diabetes Progression
    Seung-Hwan Lee, Kyu Na Lee, Jong-Chan Youn, Hun Sung Kim, Kyungdo Han, Mee Kyoung Kim
    Diabetes & Metabolism Journal.2025; 49(1): 105.     CrossRef
  • Diabetes Fact Sheets in Korea 2024
    Se Eun Park, Seung-Hyun Ko, Ji Yoon Kim, Kyuho Kim, Joon Ho Moon, Nam Hoon Kim, Kyung Do Han, Sung Hee Choi, Bong Soo Cha
    Diabetes & Metabolism Journal.2025; 49(1): 24.     CrossRef
  • Big Data Research for Diabetes-Related Diseases Using the Korean National Health Information Database
    Kyung-Soo Kim, Bongseong Kim, Kyungdo Han
    Diabetes & Metabolism Journal.2025; 49(1): 13.     CrossRef
  • Reflections on the 2024 KTA Guideline and the Role of Radioiodine Therapy in Differentiated Thyroid Cancer
    Minseok Suh, So Won Oh, Gi Jeong Cheon, June-Key Chung
    Nuclear Medicine and Molecular Imaging.2025;[Epub]     CrossRef
  • Associations Between Physical Activity and the Risk of Hip Fracture Depending on Glycemic Status: A Nationwide Cohort Study
    Kyoung Min Kim, Kyoung Jin Kim, Kyungdo Han, Yumie Rhee
    The Journal of Clinical Endocrinology & Metabolism.2024; 109(3): e1194.     CrossRef
  • Weight change in patients with new‐onset type 2 diabetes mellitus and its association with remission: Comprehensive real‐world data
    Jinyoung Kim, Bongseong Kim, Mee Kyoung Kim, Ki‐Hyun Baek, Ki‐Ho Song, Kyungdo Han, Hyuk‐Sang Kwon
    Diabetes, Obesity and Metabolism.2024; 26(2): 567.     CrossRef
  • Diabetes severity and the risk of depression: A nationwide population-based study
    Yunjung Cho, Bongsung Kim, Hyuk-Sang Kwon, Kyungdo Han, Mee Kyoung Kim
    Journal of Affective Disorders.2024; 351: 694.     CrossRef
  • Information Bias Might Exaggerate Lung Cancer Risk of Patients With Rheumatoid Arthritis
    Nobuyuki Horita, Kaoru Takase-Minegishi
    Journal of Thoracic Oncology.2024; 19(2): 348.     CrossRef
  • Diabetes Duration, Cholesterol Levels, and Risk of Cardiovascular Diseases in Individuals With Type 2 Diabetes
    Mee Kyoung Kim, Kyu Na Lee, Kyungdo Han, Seung-Hwan Lee
    The Journal of Clinical Endocrinology & Metabolism.2024; 109(12): e2317.     CrossRef
  • Risk of fracture in patients with myasthenia gravis: a nationwide cohort study in Korea
    Hye-Sun Park, Kyoungsu Kim, Min Heui Yu, Ha Young Shin, Yumie Rhee, Seung Woo Kim, Namki Hong
    Journal of Bone and Mineral Research.2024; 39(6): 688.     CrossRef
  • All-cause and cause-specific mortality risks in individuals with diabetes living alone: A large-scale population-based cohort study
    Jae-Seung Yun, Kyungdo Han, Bongseong Kim, Seung-Hyun Ko, Hyuk-Sang Kwon, Yu-Bae Ahn, Yong-Moon Mark Park, Seung-Hwan Lee
    Diabetes Research and Clinical Practice.2024; 217: 111876.     CrossRef
  • Epidemiology and Trends of Obesity and Bariatric Surgery in Korea
    Kyungdo Han, Jin-Hyung Jung, Su-Min Jeong, Mee Kyoung Kim
    Endocrinology and Metabolism.2024; 39(5): 678.     CrossRef
  • Income-Related Disparities in Mortality Among Young Adults With Type 2 Diabetes
    Ji Yoon Kim, Sojeong Park, Minae Park, Nam Hoon Kim, Sin Gon Kim
    JAMA Network Open.2024; 7(11): e2443918.     CrossRef
  • Effect of COVID-19 Vaccination on Thyroid Disease in 7 Million Adult and 0.2 Million Adolescent Vaccine Recipients
    Sungho Bea, Hwa Young Ahn, Jieun Woo, Ju-Young Shin, Sun Wook Cho
    The Journal of Clinical Endocrinology & Metabolism.2024;[Epub]     CrossRef
  • Diabetes severity is strongly associated with the risk of active tuberculosis in people with type 2 diabetes: a nationwide cohort study with a 6-year follow-up
    Ji Young Kang, Kyungdo Han, Seung-Hwan Lee, Mee Kyoung Kim
    Respiratory Research.2023;[Epub]     CrossRef
  • Research on obesity using the National Health Information Database: recent trends
    Eun-Jung Rhee
    Cardiovascular Prevention and Pharmacotherapy.2023; 5(2): 35.     CrossRef
  • Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
    Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo
    Journal of Clinical Medicine.2023; 12(14): 4799.     CrossRef
  • Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis
    Mee Kyoung Kim, Kyungdo Han, Hyuk-Sang Kwon, Soon Jib Yoo
    Endocrinology and Metabolism.2023; 38(4): 426.     CrossRef
  • Prevalence, Treatment Status, and Comorbidities of Hyperthyroidism in Korea from 2003 to 2018: A Nationwide Population Study
    Hwa Young Ahn, Sun Wook Cho, Mi Young Lee, Young Joo Park, Bon Seok Koo, Hang-Seok Chang, Ka Hee Yi
    Endocrinology and Metabolism.2023; 38(4): 436.     CrossRef
  • Is Thyroid Dysfunction Associated with Unruptured Intracranial Aneurysms? A Population-Based, Nested Case–Control Study from Korea
    Hyeree Park, Sun Wook Cho, Sung Ho Lee, Kangmin Kim, Hyun-Seung Kang, Jeong Eun Kim, Aesun Shin, Won-Sang Cho
    Thyroid®.2023; 33(12): 1483.     CrossRef
  • Risk of Cause-Specific Mortality across Glucose Spectrum in Elderly People: A Nationwide Population-Based Cohort Study
    Joonyub Lee, Hun-Sung Kim, Kee-Ho Song, Soon Jib Yoo, Kyungdo Han, Seung-Hwan Lee
    Endocrinology and Metabolism.2023; 38(5): 525.     CrossRef
  • Risk of depression in patients with acromegaly in Korea (2006-2016): a nationwide population-based study
    Shinje Moon, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    European Journal of Endocrinology.2023; 189(3): 363.     CrossRef
  • Cumulative effect of impaired fasting glucose on the risk of dementia in middle-aged and elderly people: a nationwide cohort study
    Jin Yu, Kyu-Na Lee, Hun-Sung Kim, Kyungdo Han, Seung-Hwan Lee
    Scientific Reports.2023;[Epub]     CrossRef
  • Long-Term Cumulative Exposure to High γ-Glutamyl Transferase Levels and the Risk of Cardiovascular Disease: A Nationwide Population-Based Cohort Study
    Han-Sang Baek, Bongseong Kim, Seung-Hwan Lee, Dong-Jun Lim, Hyuk-Sang Kwon, Sang-Ah Chang, Kyungdo Han, Jae-Seung Yun
    Endocrinology and Metabolism.2023; 38(6): 770.     CrossRef
  • Increased Risk of Hip Fracture in Patients with Acromegaly: A Nationwide Cohort Study in Korea
    Jiwon Kim, Namki Hong, Jimi Choi, Ju Hyung Moon, Eui Hyun Kim, Eun Jig Lee, Sin Gon Kim, Cheol Ryong Ku
    Endocrinology and Metabolism.2023; 38(6): 690.     CrossRef
Close layer
Diabetes, Obesity and Metabolism
Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
Joon Ho Moon, Kyuho Kim, Sung Hee Choi
Endocrinol Metab. 2022;37(4):575-586.   Published online August 29, 2022
DOI: https://doi.org/10.3803/EnM.2022.402
  • 28,562 View
  • 659 Download
  • 21 Web of Science
  • 24 Crossref
AbstractAbstract PDFPubReader   ePub   
High levels of triglycerides (TG) and triglyceride-rich lipoproteins (TGRLs) confer a residual risk of cardiovascular disease after optimal low-density lipoprotein cholesterol (LDL-C)–lowering therapy. Consensus has been made that LDL-C is a non-arguable primary target for lipid lowering treatment, but the optimization of TGRL for reducing the remnant risk of cardiovascular diseases is urged. Omega-3 fatty acids and fibrates are used to reduce TG levels, but many patients still have high TG and TGRL levels combined with low high-density lipoprotein concentration that need to be ideally treated. Lipoprotein lipase (LPL) is a key regulator for TGs that hydrolyzes TGs to glycerol and free fatty acids in lipoprotein particles for lipid storage and consumption in peripheral organs. A deeper understanding of human genetics has enabled the identification of proteins regulating the LPL activity, which include the apolipoproteins and angiopoietin-like families. Novel therapeutic approach such as antisense oligonucleotides and monoclonal antibodies that regulate TGs have been developed in recent decades. In this article, we focus on the biology of LPL and its modulators and review recent clinical application, including genetic studies and clinical trials of novel therapeutics. Optimization of LPL activity to lower TG levels could eventually reduce incident atherosclerotic cardiovascular disease in conjunction with successful LDL-C reduction.

Citations

Citations to this article as recorded by  
  • The Relationship Between Remnant Cholesterol and Visceral Adipose Tissue: A National Cross-Sectional Study
    Zhaoxiang Wang, Shao Zhong, Menghuan Wu, Xuejing Shao, Tian Gu, Mengjiao Xu, Qichao Yang
    Hormone and Metabolic Research.2025; 57(01): 47.     CrossRef
  • Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review
    Jakub Michal Zimodro, Manfredi Rizzo, Ioanna Gouni-Berthold
    Pharmaceuticals.2025; 18(2): 147.     CrossRef
  • The chylomicron saga: time to focus on postprandial metabolism
    Alejandro Gugliucci
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Sanghuangporus vaninii extract ameliorates hyperlipidemia in rats by mechanisms identified with transcriptome analysis
    Ning Gao, Yuanzhen Liu, Guangjie Liu, Bo Liu, Yupeng Cheng
    Food Science & Nutrition.2024; 12(5): 3360.     CrossRef
  • Targeting host-specific metabolic pathways—opportunities and challenges for anti-infective therapy
    Monika I. Konaklieva, Balbina J. Plotkin
    Frontiers in Molecular Biosciences.2024;[Epub]     CrossRef
  • Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024
    Harold Edward Bays, Carol Kirkpatrick, Kevin C. Maki, Peter P. Toth, Ryan T. Morgan, Justin Tondt, Sandra Michelle Christensen, Dave Dixon, Terry A. Jacobson
    Obesity Pillars.2024; 10: 100108.     CrossRef
  • Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review
    Chaicharn Deerochanawong, Sin Gon Kim, Yu-Cheng Chang
    Diabetes & Metabolism Journal.2024; 48(2): 184.     CrossRef
  • Xanthohumol, a prenylated chalcone, regulates lipid metabolism by modulating the LXRα/RXR-ANGPTL3-LPL axis in hepatic cell lines and high-fat diet-fed zebrafish models
    Wan-Yun Gao, Pei-Yi Chen, Hao-Jen Hsu, Je-Wen Liou, Chia-Ling Wu, Ming-Jiuan Wu, Jui-Hung Yen
    Biomedicine & Pharmacotherapy.2024; 174: 116598.     CrossRef
  • Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024
    Harold Edward Bays, Carol F. Kirkpatrick, Kevin C. Maki, Peter P. Toth, Ryan T. Morgan, Justin Tondt, Sandra Michelle Christensen, Dave L. Dixon, Terry A. Jacobson
    Journal of Clinical Lipidology.2024; 18(3): e320.     CrossRef
  • Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: A 3‐year prospective cohort study
    Ming‐Ling Chang, Jennifer Tai, Jur‐Shan Cheng, Wei‐Ting Chen, Sien‐Sing Yang, Cheng‐Hsun Chiu, Rong‐Nan Chien
    Diabetes, Obesity and Metabolism.2024; 26(7): 2969.     CrossRef
  • Efficacy and safety of omega‐3‐acid ethyl acetate 90 capsules in severe hypertriglyceridemia: A randomized, controlled, multicenter study
    Wang Zhao, Yangang Wang, Jin Li, Tao Chen, Delu Yin, Hailong Dai, Zhuhua Yao, Shuiping Zhao
    Lipids.2024; 59(5): 145.     CrossRef
  • Lipoprotein lipase as a target for obesity/diabetes related cardiovascular disease
    Rui Shang, Brian Rodrigues
    Journal of Pharmacy & Pharmaceutical Sciences.2024;[Epub]     CrossRef
  • Targeting Apolipoprotein C-III for the Management of Severe Hypertriglyceridemia: Current Research and Future Directions
    Mili Shah, Abisheikh Sharma, Mohammed Ayyad, Ethan Swartz, Danyaal Jafrani, Dhir Gala
    Cureus.2024;[Epub]     CrossRef
  • Angiopoietin-like Proteins and Lipoprotein Lipase: The Waltz Partners That Govern Triglyceride-Rich Lipoprotein Metabolism? Impact on Atherogenesis, Dietary Interventions, and Emerging Therapies
    Alejandro Gugliucci
    Journal of Clinical Medicine.2024; 13(17): 5229.     CrossRef
  • Proteo-genomic analyses in relatively lean Chinese adults identify proteins and pathways that affect general and central adiposity levels
    Andri Iona, Pang Yao, Alfred Pozarickij, Christiana Kartsonaki, Saredo Said, Neil Wright, Kuang Lin, Iona Millwood, Hannah Fry, Mohsen Mazidi, Baihan Wang, Yiping Chen, Huaidong Du, Ling Yang, Daniel Avery, Dan Schmidt, Dianjianyi Sun, Pei Pei, Jun Lv, Ca
    Communications Biology.2024;[Epub]     CrossRef
  • Molecular Pathways Linking High-Fat Diet and PM2.5 Exposure to Metabolically Abnormal Obesity: A Systematic Review and Meta-Analysis
    Sagrario Lobato, Víctor Manuel Salomón-Soto, Claudia Magaly Espinosa-Méndez, María Nancy Herrera-Moreno, Beatriz García-Solano, Ernestina Pérez-González, Facundo Comba-Marcó-del-Pont, Mireya Montesano-Villamil, Marco Antonio Mora-Ramírez, Claudia Mancilla
    Biomolecules.2024; 14(12): 1607.     CrossRef
  • High producer variant of lipoprotein lipase may protect from hepatocellular carcinoma in alcohol-associated cirrhosis
    Franziska Schmalz, Janett Fischer, Hamish Innes, Stephan Buch, Christine Möller, Madlen Matz-Soja, Witigo von Schönfels, Benjamin Krämer, Bettina Langhans, Alexandra Klüners, Michael Soyka, Felix Stickel, Jacob Nattermann, Christian P. Strassburg, Thomas
    JHEP Reports.2023; 5(4): 100684.     CrossRef
  • Measurement of Serum Low Density Lipoprotein Cholesterol and Triglyceride-Rich Remnant Cholesterol as Independent Predictors of Atherosclerotic Cardiovascular Disease: Possibilities and Limitations
    Dieter Lütjohann, Hans-Ulrich Klör, Frans Stellaard
    Nutrients.2023; 15(9): 2202.     CrossRef
  • Influence of antipsychotic medications on hyperlipidemia risk in patients with schizophrenia: evidence from a population-based cohort study and in vitro hepatic lipid homeostasis gene expression
    Tien-Yuan Wu, Ni Tien, Cheng-Li Lin, Yu-Cun Cheah, Chung Y. Hsu, Fuu-Jen Tsai, Yi-Jen Fang, Yun-Ping Lim
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux
    Alejandro Gugliucci
    Journal of Clinical Medicine.2023; 12(13): 4399.     CrossRef
  • Sugar and Dyslipidemia: A Double-Hit, Perfect Storm
    Alejandro Gugliucci
    Journal of Clinical Medicine.2023; 12(17): 5660.     CrossRef
  • Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview
    Sang Heon Suh, Soo Wan Kim
    Diabetes & Metabolism Journal.2023; 47(5): 612.     CrossRef
  • Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
    Elena Valeria Fuior, Evangelia Zvintzou, Theodosios Filippatos, Katerina Giannatou, Victoria Mparnia, Maya Simionescu, Anca Violeta Gafencu, Kyriakos E. Kypreos
    Biomedicines.2023; 11(10): 2696.     CrossRef
  • Developing a model to predict the early risk of hypertriglyceridemia based on inhibiting lipoprotein lipase (LPL): a translational study
    Julia Hernandez-Baixauli, Gertruda Chomiciute, Juan María Alcaide-Hidalgo, Anna Crescenti, Laura Baselga-Escudero, Hector Palacios-Jordan, Elisabet Foguet-Romero, Anna Pedret, Rosa M. Valls, Rosa Solà, Miquel Mulero, Josep M. Del Bas
    Scientific Reports.2023;[Epub]     CrossRef
Close layer
Original Article
Diabetes, Obesity and Metabolism
Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors
Hidefumi Inaba, Yosuke Kaido, Saya Ito, Tomonao Hirobata, Gen Inoue, Takakazu Sugita, Yuki Yamamoto, Masatoshi Jinnin, Hiroaki Kimura, Tomoko Kobayashi, Shintaro Iwama, Hiroshi Arima, Takaaki Matsuoka
Endocrinol Metab. 2022;37(1):84-95.   Published online February 28, 2022
DOI: https://doi.org/10.3803/EnM.2021.1282
  • 5,739 View
  • 187 Download
  • 22 Web of Science
  • 23 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Type 1 diabetes mellitus induced by immune-checkpoint inhibitors (ICI-T1DM) is a rare critical entity. However, the etiology of ICI-T1DM remains unclear.
Methods
In order to elucidate risk factors for ICI-T1DM, we evaluated the clinical course and immunological status of patients with ICI-T1DM who had been diagnosed during 2016 to 2021.
Results
Seven of 871 (0.8%, six men and one woman) patients developed ICI-T1DM. We revealed that the allele frequencies of human leukocyte antigen (HLA)-DPA1*02:02 and DPB1*05:01 were significantly higher in the patients with ICI-T1DM In comparison to the controls who received ICI (11/14 vs. 10/26, P=0.022; 11/14 vs. 7/26, P=0.0027, respectively). HLA-DRB1*04:05, which has been found to be a T1DM susceptibility allele in Asians, was also observed as a high-risk allele for ICI-T1DM. The significance of the HLA-DPB1*05:01 and DRB1*04:05 alleles was confirmed by an analysis of four additional patients. The absolute/relative neutrophil count, neutrophils-lymphocyte ratio, and neutrophil-eosinophil ratio increased, and the absolute lymphocyte count and absolute/relative eosinophil count decreased at the onset as compared with 6 weeks before. In two patients, alterations in cytokines and chemokines were found at the onset.
Conclusion
Novel high-risk HLA alleles and haplotypes were identified in ICI-T1DM, and peripheral blood factors may be utilized as biomarkers.

Citations

Citations to this article as recorded by  
  • Immune checkpoint inhibitor-related diabetes mellitus associated with high signal intensity in diffusion-weighted magnetic resonance imaging of the pancreas at an early clinical stage
    Masaki Suzuki, Yushi Hirota, Shin Urai, Masaaki Yamamoto, Keitaro Sofue, Wataru Ogawa
    Hormones.2025;[Epub]     CrossRef
  • Durvalumab-induced Type 1 Diabetes in a Patient With Pre-existing GADA-positive Diabetes and Preserved Insulin Secretion
    Nobuhiro Nakatake, Megumi Matsuda, Hiroki Kontani
    JCEM Case Reports.2025;[Epub]     CrossRef
  • Machine-Learning Parsimonious Prediction Model for Diagnostic Screening of Severe Hematological Adverse Events in Cancer Patients Treated with PD-1/PD-L1 Inhibitors: Retrospective Observational Study by Using the Common Data Model
    Seok Jun Park, Seungwon Yang, Suhyun Lee, Sung Hwan Joo, Taemin Park, Dong Hyun Kim, Hyeonji Kim, Soyun Park, Jung-Tae Kim, Won Gun Kwack, Sung Wook Kang, Yun-Kyoung Song, Jae Myung Cha, Sang Youl Rhee, Eun Kyoung Chung
    Diagnostics.2025; 15(2): 226.     CrossRef
  • Type 1 diabetes mellitus affected by potential toxicity from long-term use of nivolumab
    Yuma Motomura, Shin Urai, Yushi Hirota, Naoki Takegawa, Hironori Bando, Masaaki Yamamoto, Hidenori Fukuoka, Masahiro Tsuda, Wataru Ogawa
    Diabetology International.2024; 15(1): 130.     CrossRef
  • Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors
    Karlijn de Joode, Niels Heersche, Edwin A. Basak, Sander Bins, Astrid A.M. van der Veldt, Ron H.N. van Schaik, Ron H.J. Mathijssen
    Cancer Treatment Reviews.2024; 122: 102662.     CrossRef
  • Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes
    Shunya Yabuki, Hiroyuki Hirai, Chihiro Moriya, Yoshiro Kusano, Takeo Hasegawa
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Reaching the Diagnosis of Checkpoint Inhibitor-Induced Diabetes Mellitus in Different Clinical Scenarios: A Real-World Application of Updated Diagnostic Criteria
    Anna Angelousi, Dimitrios C. Ziogas, Vasiliki Siampanopoulou, Chrysoula Mytareli, Amalia Anastasopoulou, George Lyrarakis, Helen Gogas
    Diseases.2024; 12(2): 40.     CrossRef
  • Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
    Ben Ponvilawan, Abdul Wali Khan, Janakiraman Subramanian, Dhruv Bansal
    Cancers.2024; 16(6): 1225.     CrossRef
  • A case of rapidly progressive insulin-dependent diabetes mellitus without islet autoantibodies developed over two years after the first dose of nivolumab
    Kota Nishihama, Yuko Okano, Chisa Inoue, Kanako Maki, Kazuhito Eguchi, Soichiro Tanaka, Atsuro Takeshita, Mei Uemura, Taro Yasuma, Toshinari Suzuki, Esteban C. Gabazza, Yutaka Yano
    Diabetology International.2024; 15(3): 583.     CrossRef
  • HLA investigation in ICI-induced T1D and isolated ACTH deficiency including meta-analysis
    Mayo Ono, Mototsugu Nagao, Haruki Takeuchi, Etsuya Fukunaga, Tomoko Nagamine, Kyoko Inagaki, Izumi Fukuda, Masato Iwabu
    European Journal of Endocrinology.2024; 191(1): 9.     CrossRef
  • Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus
    Eleni-Rafaela Kani, Eleftheria Karaviti, Dimitra Karaviti, Eleni Gerontiti, Ioanna A. Paschou, Katerina Saltiki, Katerina Stefanaki, Theodora Psaltopoulou, Stavroula A. Paschou
    Endocrine.2024;[Epub]     CrossRef
  • Immune checkpoint inhibitor‐related type 1 diabetes incidence, risk, and survival association
    Fumika Kamitani, Yuichi Nishioka, Miyuki Koizumi, Hiroki Nakajima, Yukako Kurematsu, Sadanori Okada, Shinichiro Kubo, Tomoya Myojin, Tatsuya Noda, Tomoaki Imamura, Yutaka Takahashi
    Journal of Diabetes Investigation.2024;[Epub]     CrossRef
  • A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome
    John Marsiglio, Jordan P. McPherson, Magdalena Kovacsovics-Bankowski, Joanne Jeter, Christos Vaklavas, Umang Swami, Douglas Grossmann, Alyssa Erickson-Wayman, Heloisa P. Soares, Katie Kerrigan, Berit Gibson, Jennifer Anne Doherty, John Hyngstrom, Sheetal
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment
    Almog Shalit, Panagiotis Sarantis, Evangelos Koustas, Eleni-Myrto Trifylli, Dimitris Matthaios, Michalis V. Karamouzis
    Cancers.2023; 15(2): 375.     CrossRef
  • Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
    Iñigo Les, Mireia Martínez, Inés Pérez-Francisco, María Cabero, Lucía Teijeira, Virginia Arrazubi, Nuria Torrego, Ana Campillo-Calatayud, Iñaki Elejalde, Grazyna Kochan, David Escors
    Cancers.2023; 15(5): 1629.     CrossRef
  • Amino acid polymorphisms in human histocompatibility leukocyte antigen class II and proinsulin epitope have impacts on type 1 diabetes mellitus induced by immune-checkpoint inhibitors
    Hidefumi Inaba, Shuhei Morita, Daisuke Kosugi, Yuki Asai, Yosuke Kaido, Saya Ito, Tomonao Hirobata, Gen Inoue, Yuki Yamamoto, Masatoshi Jinnin, Hiroaki Kimura, Masao Ota, Yuko Okudaira, Hiroyasu Nakatani, Tomoko Kobayashi, Shintaro Iwama, Hiroshi Arima, T
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study
    Natsuko Hara, Hirotsugu Suwanai, Fumiyoshi Yakou, Keitaro Ishii, Hajime Iwasaki, Hironori Abe, Jumpei Shikuma, Hiroyuki Sakai, Takashi Miwa, Ryo Suzuki
    Endocrine.2023; 81(3): 477.     CrossRef
  • Autoimmunity in immune checkpoint inhibitor‐induced immune‐related adverse events: A focus on autoimmune skin toxicity and pneumonitis
    Fiamma Berner, Lukas Flatz
    Immunological Reviews.2023; 318(1): 37.     CrossRef
  • Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland
    Ichiro Yamauchi, Takuro Hakata, Taku Sugawa, Daisuke Kosugi, Haruka Fujita, Kentaro Okamoto, Yohei Ueda, Toshihito Fujii, Daisuke Taura, Norio Harada, Nobuya Inagaki
    Endocrine Journal.2023; 70(10): 987.     CrossRef
  • Key Determinants of Immune-Mediated Adverse Reactions to Oncology Drugs
    Yihan Zhou, Shan Ding
    Cancers.2023; 15(23): 5622.     CrossRef
  • Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer
    Majd Issa, Joy Tang, Yizhen Guo, Chris Coss, Thomas A. Mace, Jason Bischof, Mitch Phelps, Carolyn J Presley, Dwight H Owen
    Expert Review of Anticancer Therapy.2022; 22(8): 861.     CrossRef
  • Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
    Adithya Chennamadhavuni, Laith Abushahin, Ning Jin, Carolyn J. Presley, Ashish Manne
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Flash Glucose Monitoring and Diabetes Mellitus Induced by Immune Checkpoint Inhibitors: An Approach to Clinical Practice
    Pablo Rodríguez de Vera-Gómez, Ana Piñar-Gutiérrez, Raquel Guerrero-Vázquez, Virginia Bellido, Cristóbal Morales-Portillo, María Pilar Sancho-Márquez, Pablo Espejo-García, Noelia Gros-Herguido, Gema López-Gallardo, María Asunción Martínez-Brocca, Alfonso
    Journal of Diabetes Research.2022; 2022: 1.     CrossRef
Close layer
Brief Report
Diabetes, Obesity and Metabolism
Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies
Dimitrios Patoulias, Michael Doumas
Endocrinol Metab. 2021;36(4):904-908.   Published online July 27, 2021
DOI: https://doi.org/10.3803/EnM.2021.1048
  • 13,003 View
  • 227 Download
  • 20 Web of Science
  • 21 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
The coronavirus disease 2019 (COVID-19) pandemic remains an unbeaten enemy. Unfortunately, no targeted treatment option is available. Patients with type 2 diabetes mellitus (T2DM) have increased odds for severe or fatal disease, as demonstrated in recent observational studies. There is an ongoing discussion regarding the impact of different antidiabetic drug classes on outcomes of interest among affected subjects. Dipeptidyl peptidase-4 (DPP-4) inhibitors have been placed at the epicenter, since the DPP-4 enzyme seems to be implicated in the disease pathogenesis. Herein we present an updated meta-analysis of observational studies addressing the risk of COVID-19 death among patients with T2DM on prior DPP-4 inhibitor treatment. We pooled data from 10 observational studies, showing that DPP-4 inhibitors produce a non-significant decrease in the risk for COVID-19-related death. However, when administered in the inpatient setting, DPP-4 inhibitors decrease the risk for COVID-19-related death by 50%. Ongoing randomized controlled trials will shed further light.

Citations

Citations to this article as recorded by  
  • Effects of novel glucose-lowering drugs on the COVID-19 patients with diabetes: A network meta-analysis of clinical outcomes
    Yang Yang, Ling Zhao, Yeying Wang, Chengjiang Liu, Tingyu Ke
    International Journal of Diabetes in Developing Countries.2024; 44(3): 426.     CrossRef
  • The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies
    Zhi-Hui Song, Qiao-Ming Huang, Shan-Shan Xu, Jian-Bo Zhou, Chao Zhang
    Therapeutic Innovation & Regulatory Science.2024; 58(4): 773.     CrossRef
  • Predicting Factors of Worse Prognosis in COVID-19: Results from a Cross-sectional Study on 52 Inpatients Admitted to the Internal Medicine Department
    Giuseppe Lisco, Antonio Giovanni Solimando, Assunta Stragapede, Anna De Tullio, Cristiana Laraspata, Carola Laudadio, Vito Angelo Giagulli, Marcella Prete, Emilio Jirillo, Annalisa Saracino, Vito Racanelli, Vincenzo Triggiani
    Endocrine, Metabolic & Immune Disorders - Drug Targets.2024; 24(10): 1224.     CrossRef
  • Noninsulin‐based antihyperglycemic medications in patients with diabetes and COVID‐19: A systematic review and meta‐analysis
    Mahmoud Nassar, Hazem Abosheaishaa, Awadhesh Kumar Singh, Anoop Misra, Zachary Bloomgarden
    Journal of Diabetes.2023; 15(2): 86.     CrossRef
  • COVID-19 and metabolic syndrome
    Harsha Dissanayake
    Best Practice & Research Clinical Endocrinology & Metabolism.2023; 37(4): 101753.     CrossRef
  • Current management of diabetes patients with COVID-19
    Arup Kumar Misra, Gaurav Rangari, Madhavrao C, Sushil Sharma
    Expert Review of Endocrinology & Metabolism.2023; 18(2): 199.     CrossRef
  • Current management of diabetes patients with COVID-19
    Arup Kumar Misra, Gaurav Rangari, Madhavrao C, Sushil Sharma
    Expert Review of Endocrinology & Metabolism.2023; : 1.     CrossRef
  • Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes
    Andreana Foresta, Luisa Ojeda-Fernandez, Giulia Macaluso, Maria Carla Roncaglioni, Mauro Tettamanti, Ida Fortino, Olivia Leoni, Stefano Genovese, Marta Baviera
    Clinical Therapeutics.2023; 45(4): e115.     CrossRef
  • DPP-4 Inhibitors as a Savior for COVID-19 Patients with Diabetes
    Snehasish Nag, Samanwita Mandal, Oindrila Mukherjee, Suprabhat Mukherjee, Rakesh Kundu
    Future Virology.2023; 18(5): 321.     CrossRef
  • DrugRep-HeSiaGraph: when heterogenous siamese neural network meets knowledge graphs for drug repurposing
    Zahra Ghorbanali, Fatemeh Zare-Mirakabad, Najmeh Salehi, Mohammad Akbari, Ali Masoudi-Nejad
    BMC Bioinformatics.2023;[Epub]     CrossRef
  • Immunomodulatory activity of dipeptidyl peptidase‐4 inhibitors in immune‐related diseases
    Marija Drakul, Miodrag Čolić
    European Journal of Immunology.2023;[Epub]     CrossRef
  • Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
    Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello
    Primary Care Diabetes.2022; 16(1): 162.     CrossRef
  • Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis
    Nam Nhat Nguyen, Dung Si Ho, Hung Song Nguyen, Dang Khanh Ngan Ho, Hung-Yuan Li, Chia-Yuan Lin, Hsiao-Yean Chiu, Yang-Ching Chen
    Metabolism.2022; 131: 155196.     CrossRef
  • The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis
    Yidan Chen, Xingfei Lv, Sang Lin, Mohammad Arshad, Mengjun Dai
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Type 2 Diabetes Mellitus and COVID-19: A Narrative Review
    Cristina Rey-Reñones, Sara Martinez-Torres, Francisco M. Martín-Luján, Carles Pericas, Ana Redondo, Carles Vilaplana-Carnerero, Angela Dominguez, María Grau
    Biomedicines.2022; 10(9): 2089.     CrossRef
  • Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
    Alba Sebastián-Martín, Belén G. Sánchez, José M. Mora-Rodríguez, Alicia Bort, Inés Díaz-Laviada
    Biomedicines.2022; 10(8): 2026.     CrossRef
  • Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19
    Teodor Salmen, Valeria-Anca Pietroșel, Bianca-Margareta Mihai, Ioana Cristina Bica, Claudiu Teodorescu, Horia Păunescu, Oana Andreia Coman, Doina-Andrada Mihai, Anca Pantea Stoian
    Biomedicines.2022; 10(10): 2624.     CrossRef
  • Antidiabetic treatment and COVID-19 Outcomes: A population-based cohort study in primary health care in Catalonia during the first wave of the pandemic
    Dan Ouchi, Carles Vilaplana-Carnerero, Vanessa de Dios, Maria Giner-Soriano, Rosa Morros
    Primary Care Diabetes.2022; 16(6): 753.     CrossRef
  • Immunotropic effects of hypoglycemic agents on coronavirus infection: a view from the perspective of pharmacogenetics
    Konstantin G. Gurevich, Yulia A. Sorokina, Alexander L. Urakov, Snezhana D. Sinyushkina, Maria I. Pryazhnikova, Alyona V. Gorinova, Lyubov V. Lovtsova, Olga V. Zanozina
    Reviews on Clinical Pharmacology and Drug Therapy.2022; 20(3): 269.     CrossRef
  • Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
    Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo, Sadishkumar Kamalanathan
    World Journal of Virology.2022; 11(6): 399.     CrossRef
  • Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression
    Maria Ida Maiorino, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Paolo Chiodini, Katherine Esposito, Dario Giugliano
    Cardiovascular Diabetology.2021;[Epub]     CrossRef
Close layer
Original Article
Diabetes, Obesity and Metabolism
Big Data Articles (National Health Insurance Service Database)
The Clinical Characteristics of Gestational Diabetes Mellitus in Korea: A National Health Information Database Study
Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
Endocrinol Metab. 2021;36(3):628-636.   Published online May 26, 2021
DOI: https://doi.org/10.3803/EnM.2020.948
  • 7,480 View
  • 194 Download
  • 19 Web of Science
  • 20 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
To investigate the clinical characteristics of gestational diabetes mellitus (GDM) in Korea, using a nationwide database.
Methods
We analyzed 417,139 women who gave birth between 2011 and 2015 using the Korean National Health Information Database. They underwent the Korean National Health Screening Program within one year before pregnancy and were not prescribed drugs for diabetes nor diagnosed with diabetes mellitus before 280 days antepartum. Patients with GDM were defined as those who visited the outpatient clinic more than twice with GDM codes.
Results
The prevalence of GDM was 12.70% and increased with increasing maternal age, prepregnancy body mass index (BMI), waist circumference (WC), and fasting plasma glucose (FPG) (P for trend <0.05). As compared with those aged <25 years, the odds ratio for women with GDM aged ≥40 years were 4.804 (95% confidence interval [CI], 4.436 to 5.203) after adjustment for covariates. Women with prepregnancy BMI ≥30 kg/m2 were at 1.898 times (95% CI, 1.736 to 2.075) greater risk for GDM than those with prepregnancy BMI <18.5 kg/m2. Women with WC of ≥95 cm were at 1.158 times (95% CI, 1.029 to 1.191) greater risk for GDM than women with WC of less than 65 cm. High FPG, high income, smoking, and drinking were associated with an elevated risk of GDM.
Conclusion
The prevalence of GDM in Korean women increased up to 12.70% during 2011 to 2015. These data suggest the importance of GDM screening and prevention in high-risk groups in Korea.

Citations

Citations to this article as recorded by  
  • Circulating fibroblast growth factor 21 levels in gestational diabetes mellitus and preeclampsia: a systematic review and meta-analysis
    Zhen Cao, Zhiming Deng, Jieyi Lu, Ying Yuan
    BMC Pregnancy and Childbirth.2025;[Epub]     CrossRef
  • Big Data Research for Diabetes-Related Diseases Using the Korean National Health Information Database
    Kyung-Soo Kim, Bongseong Kim, Kyungdo Han
    Diabetes & Metabolism Journal.2025; 49(1): 13.     CrossRef
  • The problem of diabetes mellitus in obstetrics
    E.V. Popova-Petrosyan, A.A. Dovgan’, E.R. Kulieva
    Russian Bulletin of Obstetrician-Gynecologist.2024; 24(3): 25.     CrossRef
  • Relationships between triglyceride-glucose index and incident gestational diabetes mellitus: a prospective cohort study of a Korean population using publicly available data
    Zihe Mo, Changchun Cao, Yong Han, Haofei Hu, Yongcheng He, Xin Zuo
    Frontiers in Public Health.2024;[Epub]     CrossRef
  • Glucose tolerance test with a single abnormal value as a predictor of type 2 diabetes mellitus: a multicenter retrospective study
    Seon Ui Lee, Subeen Hong, Sae Kyung Choi, Su Mi Kim, Jae Eun Shin, Ki Cheol Kil, Yeon Hee Kim, Jeong Ha Wie, Yun Sung Jo, Hyun Sun Ko
    Scientific Reports.2024;[Epub]     CrossRef
  • Exploring the influence of microbiota on gestational diabetes and its potential as a biomarker
    Suresh Bokoliya, Stephanie McClellan, Yanjiao Zhou, Nini Fan
    Frontiers in Bacteriology.2024;[Epub]     CrossRef
  • Association Analysis of Dietary Inflammatory Index and Gestational Diabetes Mellitus: Based on National Health and Nutrition Examination Survey Database
    Yamin Zeng, Yina Piao
    Experimental and Clinical Endocrinology & Diabetes.2024; 132(08): 453.     CrossRef
  • Temporal Trends in Gestational Diabetes Mellitus and Associated Risk Factors in Ontario, Canada, 2012–2020: A Population-Based Cohort Study
    Rong Luo, Deshayne B. Fell, Daniel J. Corsi, Monica Taljaard, Shi Wu Wen, Mark C. Walker
    Journal of Obstetrics and Gynaecology Canada.2024; 46(8): 102573.     CrossRef
  • Amelioration of Insulin Resistance after Delivery Is Associated with Reduced Risk of Postpartum Diabetes in Women with Gestational Diabetes Mellitus
    Heejun Son, Joon Ho Moon, Sung Hee Choi, Nam H. Cho, Soo Heon Kwak, Hak Chul Jang
    Endocrinology and Metabolism.2024; 39(5): 701.     CrossRef
  • Epidemiology and long-term effects of gestational diabetes mellitus
    Geum Joon Cho, Jin Gon Bae
    Journal of the Korean Medical Association.2024; 67(11): 679.     CrossRef
  • Association of maternal dietary cholesterol intake during the second and third trimesters of pregnancy and blood glucose and pregnancy outcome in women with gestational diabetes mellitus: a prospective cohort study
    Cuiling Xie, QingXiang Zheng, Xiumin Jiang, Yanping Liao, Xiaoxia Gao, Yu Zhu, Jianing Li, Rulin Liu
    Frontiers in Nutrition.2024;[Epub]     CrossRef
  • Serum afamin levels in predicting gestational diabetes mellitus and preeclampsia: A systematic review and meta-analysis
    Ying Yuan, Wenyin He, Xuejiao Fan, Junyu Liang, Zhen Cao, Lei Li
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Smoking during pregnancy and gestational diabetes mellitus: a systematic review and meta-analysis
    Kleoniki I. Athanasiadou, Stavroula A. Paschou, Evgenia Papakonstantinou, Vasiliki Vasileiou, Fotini Kanouta, Paraskevi Kazakou, Katerina Stefanaki, Georgia N. Kassi, Theodora Psaltopoulou, Dimitrios G. Goulis, Eleni Anastasiou
    Endocrine.2023; 82(2): 250.     CrossRef
  • Association between the triglyceride to high-density lipoprotein cholesterol ratio and the risk of gestational diabetes mellitus: a second analysis based on data from a prospective cohort study
    Yun You, Haofei Hu, Changchun Cao, Yong Han, Jie Tang, Weihua Zhao
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Effects of early standardized management on the growth trajectory of offspring with gestational diabetes mellitus at 0–5 years old: a preliminary longitudinal study
    Bingbing Guo, Jingjing Pei, Yin Xu, Yajie Wang, Xinye Jiang
    Scientific Reports.2023;[Epub]     CrossRef
  • The Benefits Of Continuous Glucose Monitoring In Pregnancy
    Jee Hee Yoo, Jae Hyeon Kim
    Endocrinology and Metabolism.2023; 38(5): 472.     CrossRef
  • Gestational Diabetes Mellitus: Diagnostic Approaches and Maternal-Offspring Complications
    Joon Ho Moon, Hak Chul Jang
    Diabetes & Metabolism Journal.2022; 46(1): 3.     CrossRef
  • Current Trends of Big Data Research Using the Korean National Health Information Database
    Mee Kyoung Kim, Kyungdo Han, Seung-Hwan Lee
    Diabetes & Metabolism Journal.2022; 46(4): 552.     CrossRef
  • Maternal Gestational Diabetes Influences DNA Methylation in the Serotonin System in the Human Placenta
    Jae Yen Song, Kyung Eun Lee, Eun Jeong Byeon, Jieun Choi, Sa Jin Kim, Jae Eun Shin
    Life.2022; 12(11): 1869.     CrossRef
  • Fetal Abdominal Obesity Detected At 24 to 28 Weeks of Gestation Persists Until Delivery Despite Management of Gestational Diabetes Mellitus (Diabetes Metab J 2021;45:547-57)
    Kyung-Soo Kim
    Diabetes & Metabolism Journal.2021; 45(6): 966.     CrossRef
Close layer
Review Article
Diabetes, Obesity and Metabolism
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
Dong-Lim Kim, Seung-Eun Lee, Nan Hee Kim
Endocrinol Metab. 2023;38(1):43-55.   Published online February 27, 2023
DOI: https://doi.org/10.3803/EnM.2022.1629
  • 10,427 View
  • 1,076 Download
  • 16 Web of Science
  • 18 Crossref
AbstractAbstract PDFPubReader   ePub   
Chronic kidney disease (CKD) is the most common cause of end-stage renal disease in patients with type 2 diabetes mellitus (T2DM). CKD increases the risk of cardiovascular diseases; therefore, its prevention and treatment are important. The prevention of diabetic kidney disease (DKD) can be achieved through intensive glycemic control and blood pressure management. Additionally, DKD treatment aims to reduce albuminuria and improve kidney function. In patients with T2DM, renin-angiotensin-aldosterone system inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists can delay the progression of DKD. Hence, there is a need for novel treatments that can effectively suppress DKD progression. Finerenone is a first-in-class nonsteroidal mineralocorticoid receptor antagonist with clinically proven efficacy in improving albuminuria, estimated glomerular filtration rate, and risk of cardiovascular events in early and advanced DKD. Therefore, finerenone is a promising treatment option to delay DKD progression. This article reviews the mechanism of renal effects and major clinical outcomes of finerenone in DKD.

Citations

Citations to this article as recorded by  
  • Neue Antihypertensiva im Renin-Angiotensin-Aldosteron-System
    Markus van der Giet
    CardioVasc.2024; 24(1): 33.     CrossRef
  • Chicoric acid advanced PAQR3 ubiquitination to ameliorate ferroptosis in diabetes nephropathy through the relieving of the interaction between PAQR3 and P110α pathway
    Weiwei Zhang, Yong Liu, Jiajun Zhou, Teng Qiu, Haitang Xie, Zhichen Pu
    Clinical and Experimental Hypertension.2024;[Epub]     CrossRef
  • Endothelial CXCR2 deficiency attenuates renal inflammation and glycocalyx shedding through NF-κB signaling in diabetic kidney disease
    Siyuan Cui, Xin Chen, Jiayu Li, Wei Wang, Deqi Meng, Shenglong Zhu, Shiwei Shen
    Cell Communication and Signaling.2024;[Epub]     CrossRef
  • Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection
    Alessio Mazzieri, Francesca Porcellati, Francesca Timio, Gianpaolo Reboldi
    International Journal of Molecular Sciences.2024; 25(7): 3969.     CrossRef
  • Rediscovery of the implication of albuminuria in heart failure: emerging classic index for cardiorenal interaction
    Kyung‐Duk Min, Yuki Matsumoto, Masanori Asakura, Masaharu Ishihara
    ESC Heart Failure.2024; 11(6): 3470.     CrossRef
  • Decoding the role of aldosterone in glycation-induced diabetic complications
    Mayura Apte, Saee Zambre, Pratiksha Pisar, Bishnudeo Roy, Rashmi Tupe
    Biochemical and Biophysical Research Communications.2024; 721: 150107.     CrossRef
  • Exploring the potential of finerenone in non-diabetic chronic kidney disease: a promising frontier
    Ayesha Maryam, Muhammad Salman Nadeem, Ayesha Fatima, Kashaf Noor Asmat
    International Urology and Nephrology.2024; 57(1): 295.     CrossRef
  • A new perspective on proteinuria and drug therapy for diabetic kidney disease
    Ruimin Zhang, Qian Wang, Yaqing Li, Qihu Li, Xuefeng Zhou, Xiangmei Chen, Zheyi Dong
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Molecular Therapeutics for Diabetic Kidney Disease: An Update
    Man Guo, Fangfang He, Chun Zhang
    International Journal of Molecular Sciences.2024; 25(18): 10051.     CrossRef
  • Pharmacokinetic and Pharmacodynamic Interaction of Finerenone with Diltiazem, Fluconazole, and Ritonavir in Rats
    Tham Thi Bui, So-Hyeon Kim, Woojin Jung, Sung-yoon Yang, Quyen Thi Tran, Hyunjung Lee, Seongwon Park, Lien Thi Ngo, Hwi-yeol Yun, Jung-woo CHAE
    European Journal of Drug Metabolism and Pharmacokinetics.2024; 49(6): 701.     CrossRef
  • A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
    Shuhui Zhai, Baisheng Ma, Weiwei Chen, Qini Zhao
    Frontiers in Cardiovascular Medicine.2024;[Epub]     CrossRef
  • Exercise as a therapeutic approach to alleviate diabetic kidney disease: mechanisms, clinical evidence and potential exercise prescriptions
    Rao Fan, Jianda Kong, Jiahao Zhang, Lei Zhu
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Omics Studies in CKD: Diagnostic Opportunities and Therapeutic Potential
    Merita Rroji, Goce Spasovski
    PROTEOMICS.2024;[Epub]     CrossRef
  • Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?
    Alessio Mazzieri, Francesca Timio, Francesco Patera, Francesco Trepiccione, Mario Bonomini, Gianpaolo Reboldi
    Kidney and Blood Pressure Research.2024; 49(1): 1041.     CrossRef
  • Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease
    Akshyaya Pradhan, Umesh Chandra Tripathi
    The Egyptian Heart Journal.2024;[Epub]     CrossRef
  • Epigenetic modification in diabetic kidney disease
    Zhe Liu, Jiahui Liu, Wanning Wang, Xingna An, Ling Luo, Dehai Yu, Weixia Sun
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Novel Approaches in Chronic Renal Failure without Renal Replacement Therapy: A Review
    Sandra Martínez-Hernández, Martín Muñoz-Ortega, Manuel Ávila-Blanco, Mariana Medina-Pizaño, Javier Ventura-Juárez
    Biomedicines.2023; 11(10): 2828.     CrossRef
  • Finerenone and other future therapeutic options for Alport syndrome
    Helen Pearce, Holly Mabillard
    Journal of Rare Diseases.2023;[Epub]     CrossRef
Close layer
Original Articles
Diabetes, Obesity and Metabolism
Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials
Shinje Moon, Jibeom Lee, Hye Soo Chung, Yoon Jung Kim, Jae Myung Yu, Sung Hoon Yu, Chang-Myung Oh
Endocrinol Metab. 2021;36(3):647-660.   Published online June 18, 2021
DOI: https://doi.org/10.3803/EnM.2020.934
  • 7,946 View
  • 326 Download
  • 18 Web of Science
  • 18 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Obesity is a chronic disease associated with metabolic diseases such as diabetes and cardiovascular disease. Since the U.S. Food and Drug Administration approved liraglutide as an anti-obesity drug for nondiabetic patients in 2014, it has been widely used for weight control in overweight and obese people. This study aimed to systematically analyze the effects of liraglutide on body weight and other cardiometabolic parameters.
Methods
We investigated articles from PubMed, EMBASE, and the Cochrane Library to search randomized clinical trials that examined body weight changes with liraglutide treatment.
Results
We included 31 studies with 8,060 participants for this meta-analysis. The mean difference (MD) between the liraglutide group and the placebo group was −4.19 kg (95% confidence interval [CI], −4.84 to −3.55), with a −4.16% change from the baseline (95% CI, −4.90 to −3.43). Liraglutide treatment correlated with a significantly reduced body mass index (MD: −1.55; 95% CI, −1.76 to −1.34) and waist circumference (MD: −3.11 cm; 95% CI, −3.59 to −2.62) and significantly decreased blood pressure (systolic blood pressure, MD: −2.85 mm Hg; 95% CI, −3.36 to −2.35; diastolic blood pressure, MD: −0.66 mm Hg; 95% CI, −1.02 to −0.30), glycated hemoglobin (MD: −0.40%; 95% CI, −0.49 to −0.31), and low-density lipoprotein cholesterol (MD: –2.91 mg/dL; 95% CI, −5.28 to −0.53; MD: −0.87% change from baseline; 95% CI, −1.17 to −0.56).
Conclusion
Liraglutide is effective for weight control and can be a promising drug for cardiovascular protection in overweight and obese people.

Citations

Citations to this article as recorded by  
  • Pharmacotherapy for obesity: moving towards efficacy improvement
    Walmir Coutinho, Bruno Halpern
    Diabetology & Metabolic Syndrome.2024;[Epub]     CrossRef
  • Physiopathology and Treatment of Obesity and Overweight: A Proposal for a New Anorectic
    Bruno Silvestrini, Mauro Silvestrini, Mayank Choubey
    Journal of Obesity.2024; 2024: 1.     CrossRef
  • Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model
    Katerina Horska, Jan Kucera, Eva Drazanova, Gabriela Kuzminova, Petra Amchova, Maria Hrickova, Jana Ruda-Kucerova, Silje Skrede
    Biomedicine & Pharmacotherapy.2024; 176: 116763.     CrossRef
  • Association between weight loss and cardiovascular outcomes and mortality in Korea: A nationwide cohort study
    So Yoon Kwon, Gyuri Kim, Seohyun Kim, Jae Hyeon Kim
    Diabetes Research and Clinical Practice.2024; 214: 111767.     CrossRef
  • Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
    Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao
    Signal Transduction and Targeted Therapy.2024;[Epub]     CrossRef
  • De la découverte des hormones incrétines aux doubles et triples agonistes GIP / GLP-1 / glucagon
    Franck Phan, Romane Bertrand, Chloé Amouyal, Fabrizio Andreelli
    médecine/sciences.2024; 40(11): 837.     CrossRef
  • Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis
    Yilin Li, Rong Lei, Honglin Lei, Qin Xiong, Fengjiao Xie, Chengjiao Yao, Peimin Feng
    European Journal of Gastroenterology & Hepatology.2023; 35(1): 1.     CrossRef
  • Recommendations for the prevention and management of obesity in the Iraqi population
    Hussein Ali Nwayyir, Esraa Majid Mutasher, Osama Mohammed Alabid, Muthana Abdulrazzaq Jabbar, Wefak Hasan Abdulraheem Al-Kawaz, Haider Ayad Alidrisi, Majid Alabbood, Muhammed Chabek, Munib AlZubaidi, Lujain Anwar Al-khazrajy, Ibtihal Shukri Abd Alhaleem,
    Postgraduate Medicine.2023; 135(5): 425.     CrossRef
  • A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
    Fatma Haddad, Ghadeer Dokmak, Maryam Bader, Rafik Karaman
    Life.2023; 13(4): 1012.     CrossRef
  • Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice
    Juyoung Shin, Raeun Kim, Hun-Sung Kim
    Cardiovascular Prevention and Pharmacotherapy.2023; 5(2): 49.     CrossRef
  • The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials
    Pejman Rohani, Nasser Malekpour Alamdari, Seyedeh Elaheh Bagheri, Azita Hekmatdoost, Mohammad Hassan Sohouli
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials
    Hao Gou, Yiman Zhai, Junjun Guo
    European Journal of Pediatrics.2023; 182(11): 5095.     CrossRef
  • Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis
    Ping Zhong, Hai Zeng, Miaochun Huang, Wenbin Fu, Zhixia Chen
    Endocrine.2022; 75(3): 718.     CrossRef
  • Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
    David C. W. Lau, Rachel L Batterham, Carel W. le Roux
    Expert Review of Clinical Pharmacology.2022; 15(3): 251.     CrossRef
  • Pharmacological Management of Obesity: A Century of Expert Opinions in Cecil Textbook of Medicine
    Peter Manu, Cristina-Mihaela Lăcătuşu, Liliana M. Rogozea, Simona Cernea
    American Journal of Therapeutics.2022; 29(4): e410.     CrossRef
  • GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?
    Katerina Horska, Jana Ruda-Kucerova, Silje Skrede
    Trends in Endocrinology & Metabolism.2022; 33(9): 628.     CrossRef
  • Targeting skeletal muscle mitochondrial health in obesity
    Chantal A. Pileggi, Breana G. Hooks, Ruth McPherson, Robert R.M. Dent, Mary-Ellen Harper
    Clinical Science.2022; 136(14): 1081.     CrossRef
  • A Study on Weight Loss Cause as per the Side Effect of Liraglutide
    Jin Yu, Jeongmin Lee, Seung-Hwan Lee, Jae-Hyung Cho, Hun-Sung Kim, Heng Zhou
    Cardiovascular Therapeutics.2022; 2022: 1.     CrossRef
Close layer
Diabetes, Obesity and Metabolism
Short-Chain Fatty Acids Attenuate Renal Fibrosis and Enhance Autophagy of Renal Tubular Cells in Diabetic Mice Through the HDAC2/ULK1 Axis
Xiaoying Ma, Qiong Wang
Endocrinol Metab. 2022;37(3):432-443.   Published online May 16, 2022
DOI: https://doi.org/10.3803/EnM.2021.1336
  • 8,587 View
  • 170 Download
  • 14 Web of Science
  • 16 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
This study investigated the effect of short-chain fatty acids (SCFAs) on diabetes in a mouse model.
Methods
Autophagy in Akita mice and streptozocin (STZ)-induced diabetic C57BL/6 mice was determined by Western blots and immunohistochemistry (IHC). Western blots, IHC, hematoxylin and eosin staining, Masson staining, periodic acid-Schiff staining, and picrosirius red staining were conducted to detect whether autophagy and renal function improved in Akita mice and STZ-induced diabetic C57BL/6 mice after treatment of SCFAs. Western blots, IHC, and chromatin immunoprecipitation were performed to determine whether SCFAs affected diabetic mice via the histone deacetylase (HDAC2)/unc-51 like autophagy activating kinase 1 (ULK1) axis. Diabetic mice with kidney-specific knockout of HDAC2 were constructed, and IHC, Masson staining, and Western blots were carried out to detect whether the deletion of endogenous HDAC2 contributed to the improvement of autophagy and renal fibrosis in diabetic mice.
Results
Reduced autophagy and severe fibrosis were observed in Akita mice and STZ-induced diabetic C57BL/6 mice. Increased autophagy and reduced renal cell fibrosis were found in SCFA-treated Akita diabetic mice and STZ-induced diabetic C57BL/6 mice. Diabetic mice treated with SCFAs had lower HDAC2 expression and more enriched binding of ULK1 promoter sequences to H3K27Ac. Endogenous knockout of HDAC2 caused enhanced autophagy and decreased renal fibrosis in diabetic mice treated with SCFAs.
Conclusion
SCFAs enhanced autophagy of renal tubular cells and attenuated renal fibrosis in diabetic mice through the HDAC2/ULK1 axis.

Citations

Citations to this article as recorded by  
  • Recent advances and potentiality of postbiotics in the food industry: Composition, inactivation methods, current applications in metabolic syndrome, and future trends
    Yujie Zhong, Tao Wang, Ruilin Luo, Jiayu Liu, Ruyi Jin, Xiaoli Peng
    Critical Reviews in Food Science and Nutrition.2024; 64(17): 5768.     CrossRef
  • NSD1 supports cell growth and regulates autophagy in HPV-negative head and neck squamous cell carcinoma
    Iuliia Topchu, Igor Bychkov, Demirkan Gursel, Petr Makhov, Yanis Boumber
    Cell Death Discovery.2024;[Epub]     CrossRef
  • Dietary fiber intake and its association with diabetic kidney disease in American adults with diabetes: A cross-sectional study
    Xin-Hua Jia, Sheng-Yan Wang, Ai-Qin Sun
    World Journal of Diabetes.2024; 15(3): 475.     CrossRef
  • Role of Histone Modifications in Kidney Fibrosis
    Shengyu Pan, Tianhui Yuan, Yuqi Xia, Weimin Yu, Xiangjun Zhou, Fan Cheng
    Medicina.2024; 60(6): 888.     CrossRef
  • ULK1 as a therapeutic target in kidney diseases: Current perspective
    Shruti Shreya, Neha Dagar, Vishwadeep Shelke, Bhupendra Puri, Anil Bhanudas Gaikwad
    Expert Opinion on Therapeutic Targets.2024; 28(10): 911.     CrossRef
  • Role of Epigenetic Changes in the Pathophysiology of Diabetic Kidney Disease
    Marita Liebisch, Gunter Wolf
    Glomerular Diseases.2024; 4(1): 211.     CrossRef
  • N-acetyltransferase 10 regulates UNC-51-like kinase 1 to reduce tubular cell injury and kidney stone formation
    Le Wang, Jinjing Huang, Lei Song, Ben Ke
    Cytojournal.2024; 21: 68.     CrossRef
  • Epigenetic and post-translational modifications in autophagy: biological functions and therapeutic targets
    Feng Shu, Han Xiao, Qiu-Nuo Li, Xiao-Shuai Ren, Zhi-Gang Liu, Bo-Wen Hu, Hong-Sheng Wang, Hao Wang, Guan-Min Jiang
    Signal Transduction and Targeted Therapy.2023;[Epub]     CrossRef
  • Mechanisms of Blood–Brain Barrier Protection by Microbiota-Derived Short-Chain Fatty Acids
    Ekaterina Fock, Rimma Parnova
    Cells.2023; 12(4): 657.     CrossRef
  • The Role of Histone Modifications in the Pathogenesis of Diabetic Kidney Disease
    Christodoula Kourtidou, Konstantinos Tziomalos
    International Journal of Molecular Sciences.2023; 24(6): 6007.     CrossRef
  • Mechanism of histone deacetylase HDAC2 in FOXO3-mediated trophoblast pyroptosis in preeclampsia
    Jia Liu, Weihui Yang
    Functional & Integrative Genomics.2023;[Epub]     CrossRef
  • Macrophage polarization induces endothelium-to-myofibroblast transition in chronic allograft dysfunction
    Zeping Gui, Xiang Zhang, Qianguang Han, Zhou Hang, Ruoyun Tan, Min Gu, Zijie Wang
    Renal Failure.2023;[Epub]     CrossRef
  • Periodic acid–Schiff staining in oral exfoliative cytology of diabetic patients: The odyssey for noninvasive screening – A systematic review and meta-analysis
    K. Yesoda Aniyan, Krithika Chandrasekar Lakshmi, Anuradha Ganesan
    Dental Research Journal.2023;[Epub]     CrossRef
  • Luteolin alleviates renal ischemia-reperfusion injury in streptozotocin induced diabetic rats by inhibiting metalloenzymes expression
    Rakesh B. Daude, Jigna S. Shah
    Current Issues in Pharmacy and Medical Sciences.2023; 36(4): 199.     CrossRef
  • Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression
    Jiayu Wang, Jiaxing Li, Xin Zhang, Min Zhang, Xiaopeng Hu, Hang Yin
    Frontiers in Molecular Biosciences.2022;[Epub]     CrossRef
  • Sacubitril/Valsartan contributes to improving the diabetic kidney disease and regulating the gut microbiota in mice
    Peipei Wang, Ruixue Guo, Xiwen Bai, Wen Cui, Yiding Zhang, Huangmin Li, Jin Shang, Zhanzheng Zhao
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
Close layer
Diabetes, Obesity and Metabolism
The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE−/−FXR−/− Mice
Yenna Lee, Bo-Rahm Kim, Geun-Hyung Kang, Gwan Jae Lee, Young Joo Park, Haeryoung Kim, Hak Chul Jang, Sung Hee Choi
Endocrinol Metab. 2021;36(6):1243-1253.   Published online December 28, 2021
DOI: https://doi.org/10.3803/EnM.2021.1100
  • 7,230 View
  • 173 Download
  • 15 Web of Science
  • 16 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Farnesoid X receptor (FXR), a bile acid–activated nuclear receptor, is a potent regulator of glucose and lipid metabolism as well as of bile acid metabolism. Previous studies have demonstrated that FXR deficiency is associated with metabolic derangements, including atherosclerosis and nonalcoholic fatty liver disease (NAFLD), but its mechanism remains unclear. In this study, we investigated the role of FXR in atherosclerosis and NAFLD and the effect of peroxisome proliferator-activated receptor (PPAR) agonists in mouse models with FXR deficiency.
Methods
En face lipid accumulation analysis, liver histology, serum levels of glucose and lipids, and mRNA expression of genes related to lipid metabolism were compared between apolipoprotein E (ApoE)−/− and ApoE−/−FXR−/− mice. The effects of PPARα and PPARγ agonists were also compared in both groups of mice.
Results
Compared with ApoE−/− mice, ApoE−/−FXR−/− mice showed more severe atherosclerosis, hepatic steatosis, and higher levels of serum cholesterol, low-density lipoprotein cholesterol, and triglycerides, accompanied by increased mRNA expression of FAS, ApoC2, TNFα, IL-6 (liver), ATGL, TGH, HSL, and MGL (adipocytes), and decreased mRNA expressions of CPT2 (liver) and Tfam (skeletal muscle). Treatment with a PPARα agonist, but not with a PPARγ agonist, partly reversed atherosclerosis and hepatic steatosis, and decreased plasma triglyceride levels in the ApoE−/−FXR−/− mice, in association with increased mRNA expression of CD36 and FATP and decreased expression of ApoC2 and ApoC3 (liver).
Conclusion
Loss of FXR is associated with aggravation of atherosclerosis and hepatic steatosis in ApoE-deficient mice, which could be reversed by a PPARα agonist through induction of fatty acid uptake, β-oxidation, and triglyceride hydrolysis.

Citations

Citations to this article as recorded by  
  • Evaluation of the hepatotoxicity of Psoralea corylifolia L. based on a zebrafish model
    Shu-Yan Gao, Jing-Cheng Zhao, Qing Xia, Chen Sun, Maimaiti Aili, Ainiwaer Talifu, Shi-Xia Huo, Yun Zhang, Zhi-Jian Li
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
    Yuxiao Jiang, Lili Wu, Xiaopeng Zhu, Hua Bian, Xin Gao, Mingfeng Xia
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver disease
    Milton Boaheng Antwi, Ariann Jennings, Sander Lefere, Dorien Clarisse, Anja Geerts, Lindsey Devisscher, Karolien De Bosscher
    npj Metabolic Health and Disease.2024;[Epub]     CrossRef
  • Monomethyl Branched‐Chain Fatty Acids Suppress M1 Macrophage Polarization via FABP4/PPAR‐γ Signaling Pathway
    Yuan He, Yu Zhang, Shuang Zhu, Yuan‐fa Liu, Sha Liu, Yong‐jiang Xu
    Molecular Nutrition & Food Research.2024;[Epub]     CrossRef
  • COL6A6 Peptide Vaccine Alleviates Atherosclerosis through Inducing Immune Response and Regulating Lipid Metabolism in Apoe−/− Mice
    Dongmei Tang, Yan Liu, Rui Duan, Run Lin, Zhonghao Li, Xianyan Liu, Jingrong Huang, Ming Zhao
    Cells.2024; 13(18): 1589.     CrossRef
  • Mitochondrial carnitine palmitoyltransferase-II dysfunction: A possible novel mechanism for nonalcoholic fatty liver disease in hepatocarcinogenesis
    Min Yao, Ping Zhou, Yan-Yan Qin, Li Wang, Deng-Fu Yao
    World Journal of Gastroenterology.2023; 29(12): 1765.     CrossRef
  • Emerging Roles of Gut Microbial Modulation of Bile Acid Composition in the Etiology of Cardiovascular Diseases
    Tess Yntema, Debby P. Y. Koonen, Folkert Kuipers
    Nutrients.2023; 15(8): 1850.     CrossRef
  • The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
    Alexandra C. Finney, Sandeep Das, Dhananjay Kumar, M. Peyton McKinney, Bishuang Cai, Arif Yurdagul, Oren Rom
    Frontiers in Cardiovascular Medicine.2023;[Epub]     CrossRef
  • Targeting PPARs for therapy of atherosclerosis: A review
    Miao Miao, Xue Wang, Tian Liu, Yan-Jie Li, Wen-Qian Yu, Tong-Mei Yang, Shou-Dong Guo
    International Journal of Biological Macromolecules.2023; 242: 125008.     CrossRef
  • Cabernet sauvignon dry red wine ameliorates atherosclerosis in mice by regulating inflammation and endothelial function, activating AMPK phosphorylation, and modulating gut microbiota
    Xinlong Cheng, Xue Han, Liangfu Zhou, Yasai Sun, Qian Zhou, Xuan Lin, Zhe Gao, Jie Wang, Wen Zhao
    Food Research International.2023; 169: 112942.     CrossRef
  • Impacts of dietary lipids derived from animal or vegetable sources on healthy rats
    Mostafa M Dalal, Gamal M Edrees, Hanaa A Hassan, Mamdouh Abdel-Mogib, Mai Alaa El-Dein
    Egyptian Journal of Basic and Applied Sciences.2023; 10(1): 618.     CrossRef
  • Whey protein hydrolysate alleviated atherosclerosis and hepatic steatosis by regulating lipid metabolism in apoE-/- mice fed a Western diet
    Kai Wang, Zixin Fu, Xiaoyi Li, Hui Hong, Xin Zhan, Xiaohong Guo, Yongkang Luo, Yuqing Tan
    Food Research International.2022; 157: 111419.     CrossRef
  • Melatonin alleviates PM2.5‐induced glucose metabolism disorder and lipidome alteration by regulating endoplasmic reticulum stress
    Zhou Du, Junjie Hu, Lisen Lin, Qingqing Liang, Mengqi Sun, Zhiwei Sun, Junchao Duan
    Journal of Pineal Research.2022;[Epub]     CrossRef
  • Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
    Joon Ho Moon, Kyuho Kim, Sung Hee Choi
    Endocrinology and Metabolism.2022; 37(4): 575.     CrossRef
  • The role of the gut microbiota in health and cardiovascular diseases
    Lu Wang, Shiqi Wang, Qing Zhang, Chengqi He, Chenying Fu, Quan Wei
    Molecular Biomedicine.2022;[Epub]     CrossRef
Close layer
Review Article
Diabetes, Obesity and Metabolism
Homeostatic Regulation of Glucose Metabolism by the Central Nervous System
Jong Han Choi, Min-Seon Kim
Endocrinol Metab. 2022;37(1):9-25.   Published online February 28, 2022
DOI: https://doi.org/10.3803/EnM.2021.1364
  • 9,426 View
  • 475 Download
  • 13 Web of Science
  • 15 Crossref
AbstractAbstract PDFPubReader   ePub   
Evidence for involvement of the central nervous system (CNS) in the regulation of glucose metabolism dates back to the 19th century, although the majority of the research on glucose metabolism has focused on the peripheral metabolic organs. Due to recent advances in neuroscience, it has now become clear that the CNS is indeed vital for maintaining glucose homeostasis. To achieve normoglycemia, specific populations of neurons and glia in the hypothalamus sense changes in the blood concentrations of glucose and of glucoregulatory hormones such as insulin, leptin, glucagon-like peptide 1, and glucagon. This information is integrated and transmitted to other areas of the brain where it eventually modulates various processes in glucose metabolism (i.e., hepatic glucose production, glucose uptake in the brown adipose tissue and skeletal muscle, pancreatic insulin and glucagon secretion, renal glucose reabsorption, etc.). Errors in these processes lead to hyper- or hypoglycemia. We here review the current understanding of the brain regulation of glucose metabolism.

Citations

Citations to this article as recorded by  
  • Sympathetic nerve-enteroendocrine L cell communication modulates GLP-1 release, brain glucose utilization, and cognitive function
    Wenran Ren, Jianhui Chen, Wenjing Wang, Qingqing Li, Xia Yin, Guanglei Zhuang, Hong Zhou, Wenwen Zeng
    Neuron.2024; 112(6): 972.     CrossRef
  • Hypothalamic astrocyte NAD+ salvage pathway mediates the coupling of dietary fat overconsumption in a mouse model of obesity
    Jae Woo Park, Se Eun Park, Wuhyun Koh, Won Hee Jang, Jong Han Choi, Eun Roh, Gil Myoung Kang, Seong Jun Kim, Hyo Sun Lim, Chae Beom Park, So Yeon Jeong, Sang Yun Moon, Chan Hee Lee, Sang Yeob Kim, Hyung Jin Choi, Se Hee Min, C. Justin Lee, Min-Seon Kim
    Nature Communications.2024;[Epub]     CrossRef
  • Efficacy of metformin and electrical pulses in breast cancer MDA-MB-231 cells
    Praveen Sahu, Ignacio G. Camarillo, Raji Sundararajan
    Exploration of Targeted Anti-tumor Therapy.2024; 5(1): 54.     CrossRef
  • Redox imbalance and metabolic defects in the context of Alzheimer disease
    Fabio Di Domenico, Chiara Lanzillotta, Marzia Perluigi
    FEBS Letters.2024;[Epub]     CrossRef
  • Acid sphingomyelinase inhibition induces cerebral angiogenesis post-ischemia/reperfusion in an oxidative stress-dependent way and promotes endothelial survival by regulating mitochondrial metabolism
    Ayan Mohamud Yusuf, Mina Borbor, Tanja Hussner, Carolin Weghs, Britta Kaltwasser, Matthias Pillath-Eilers, Bernd Walkenfort, Richard Kolesnick, Erich Gulbins, Dirk M. Hermann, Ulf Brockmeier
    Cell Death & Disease.2024;[Epub]     CrossRef
  • Antipsychotic-Induced Dysregulation of Glucose Metabolism Through the Central Nervous System: A Scoping Review of Animal Models
    Emily Au, Kristoffer J. Panganiban, Sally Wu, Kira Sun, Bailey Humber, Gary Remington, Sri Mahavir Agarwal, Adria Giacca, Sandra Pereira, Margaret Hahn
    Biological Psychiatry: Cognitive Neuroscience and Neuroimaging.2024;[Epub]     CrossRef
  • Brown Fat and Metabolic Health: The Diverse Functions of Dietary Components
    Zachary Brown, Takeshi Yoneshiro
    Endocrinology and Metabolism.2024; 39(6): 839.     CrossRef
  • Neuronal Regulation of Feeding and Energy Metabolism: A Focus on the Hypothalamus and Brainstem
    Jing Chen, Meiting Cai, Cheng Zhan
    Neuroscience Bulletin.2024;[Epub]     CrossRef
  • Obesity-associated microglial inflammatory activation paradoxically improves glucose tolerance
    John D. Douglass, Kelly M. Ness, Martin Valdearcos, Alice Wyse-Jackson, Mauricio D. Dorfman, Jeremy M. Frey, Rachael D. Fasnacht, Olivia D. Santiago, Anzela Niraula, Jineta Banerjee, Megan Robblee, Suneil K. Koliwad, Joshua P. Thaler
    Cell Metabolism.2023; 35(9): 1613.     CrossRef
  • Phenotypic screening using waveform analysis of synchronized calcium oscillations in primary cortical cultures
    Richi Sakaguchi, Saki Nakamura, Hiroyuki Iha, Masaki Tanaka, Ming Tatt Lee
    PLOS ONE.2023; 18(4): e0271782.     CrossRef
  • Effects of Escitalopram on the Functional Neural Circuits in an Animal Model of Adolescent Depression
    Se Jong Oh, Namhun Lee, Kyung Rok Nam, Kyung Jun Kang, Sang Jin Han, Jae Yong Choi
    Molecular Imaging and Biology.2023; 25(4): 735.     CrossRef
  • A Survey of Deep Learning for Alzheimer’s Disease
    Qinghua Zhou, Jiaji Wang, Xiang Yu, Shuihua Wang, Yudong Zhang
    Machine Learning and Knowledge Extraction.2023; 5(2): 611.     CrossRef
  • Potassium channels in behavioral brain disorders. Molecular mechanisms and therapeutic potential: A narrative review
    Kazi Asraful Alam, Pernille Svalastoga, Aurora Martinez, Jeffrey Colm Glennon, Jan Haavik
    Neuroscience & Biobehavioral Reviews.2023; 152: 105301.     CrossRef
  • Knockout of Nur77 Leads to Amino Acid, Lipid, and Glucose Metabolism Disorders in Zebrafish
    Yang Xu, Juanjuan Tian, Qi Kang, Hang Yuan, Chengdong Liu, Zhehui Li, Jie Liu, Mingyu Li
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Effects of the POMC System on Glucose Homeostasis and Potential Therapeutic Targets for Obesity and Diabetes
    Dan Yang, Xintong Hou, Guimei Yang, Mengnan Li, Jian Zhang, Minmin Han, Yi Zhang, Yunfeng Liu
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 2939.     CrossRef
Close layer
Original Articles
Diabetes, obesity and metabolism
Triglyceride-Glucose Index Predicts Future Atherosclerotic Cardiovascular Diseases: A 16-Year Follow-up in a Prospective, Community-Dwelling Cohort Study
Joon Ho Moon, Yongkang Kim, Tae Jung Oh, Jae Hoon Moon, Soo Heon Kwak, Kyong Soo Park, Hak Chul Jang, Sung Hee Choi, Nam H. Cho
Endocrinol Metab. 2023;38(4):406-417.   Published online August 3, 2023
DOI: https://doi.org/10.3803/EnM.2023.1703
  • 8,343 View
  • 260 Download
  • 11 Web of Science
  • 15 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
While the triglyceride-glucose (TyG) index is a measure of insulin resistance, its association with cardiovascular disease (CVD) has not been well elucidated. We evaluated the TyG index for prediction of CVDs in a prospective large communitybased cohort.
Methods
Individuals 40 to 70 years old were prospectively followed for a median 15.6 years. The TyG index was calculated as the Ln [fasting triglycerides (mg/dL)×fasting glucose (mg/dL)/2]. CVDs included any acute myocardial infarction, coronary artery disease or cerebrovascular disease. We used a Cox proportional hazards model to estimate CVD risks according to quartiles of the TyG index and plotted the receiver operating characteristics curve for the incident CVD.
Results
Among 8,511 subjects (age 51.9±8.8 years; 47.5% males), 931 (10.9%) had incident CVDs during the follow-up. After adjustment for age, sex, body mass index, diabetes mellitus, hypertension, total cholesterol, smoking, alcohol, exercise, and C-reactive protein, subjects in the highest TyG quartile had 36% increased risk of incident CVD compared with the lowest TyG quartile (hazard ratio, 1.36; 95% confidence interval, 1.10 to 1.68). Carotid plaque, assessed by ultrasonography was more frequent in subjects in the higher quartile of TyG index (P for trend=0.049 in men and P for trend <0.001 in women). The TyG index had a higher predictive power for CVDs than the homeostasis model assessment of insulin resistance (HOMA-IR) (area under the curve, 0.578 for TyG and 0.543 for HOMA-IR). Adding TyG index on diabetes or hypertension alone gave sounder predictability for CVDs.
Conclusion
The TyG index is independently associated with future CVDs in 16 years of follow-up in large, prospective Korean cohort.

Citations

Citations to this article as recorded by  
  • Elevated triglyceride-glucose index as a predictor of carotid plaque incidence: Insights from a comprehensive meta-analysis
    Arankesh Mahadevan, Bhavin A. Patel, Sashwath Srikanth, Raja Godasi, Rupak Desai
    The American Journal of the Medical Sciences.2025; 369(2): 197.     CrossRef
  • Analysis of the correlation between the serum triglyceride glucose index and the risk of death in patients on maintenance hemodialysis: a retrospective cohort study
    Xiaokeng Chi, Shuxin Chen, Zhe Huang, Rong Zhou, Zhicheng Su, Qiujun Mai, Yilin Xu, Jianxin Wan
    PeerJ.2025; 13: e18781.     CrossRef
  • Assessing the predictive value of elevated triglycerides, triglyceride-glucose index (TyG), and TG/HDL ratios for cardiovascular disease and mortality during 20 years of follow-up: Tehran lipid and glucose study
    Shayesteh Khalili, Atieh Amouzegar, Seyed Sattar Dorost, Fereidoun Azizi, Aryan Salahi-Niri
    Clinical Biochemistry.2025; 136: 110891.     CrossRef
  • Association between triglyceride-glucose index and carotid atherosclerosis in Chinese steelworkers: a cross-sectional study
    Haoyue Cao, Qinglin Li, Juxiang Yuan
    Scientific Reports.2025;[Epub]     CrossRef
  • Construction and validation of a nomogram for predicting diabetes remission at 3 months after bariatric surgery in patients with obesity combined with type 2 diabetes mellitus
    Kaisheng Yuan, Bing Wu, Ruiqi Zeng, Fuqing Zhou, Ruixiang Hu, Cunchuan Wang
    Diabetes, Obesity and Metabolism.2024; 26(1): 169.     CrossRef
  • Association between the triglyceride glucose index and chronic total coronary occlusion: A cross-sectional study from southwest China
    Kaiyong Xiao, Huili Cao, Bin Yang, Zhe Xv, Lian Xiao, Jianping Wang, Shuiqing Ni, Hui Feng, Zhongwei He, Lei Xv, Juan Li, Dongmei Xv
    Nutrition, Metabolism and Cardiovascular Diseases.2024; 34(4): 850.     CrossRef
  • The association between TyG and all-cause/non-cardiovascular mortality in general patients with type 2 diabetes mellitus is modified by age: results from the cohort study of NHANES 1999–2018
    Younan Yao, Bo Wang, Tian Geng, Jiyan Chen, Wan Chen, Liwen Li
    Cardiovascular Diabetology.2024;[Epub]     CrossRef
  • Comparison of triglyceride glucose index and modified triglyceride glucose indices in prediction of cardiovascular diseases in middle aged and older Chinese adults
    Cancan Cui, Yitian Qi, Jiayin Song, Xinyun Shang, Tianjiao Han, Ning Han, Siqi Yue, Yining Zha, Zhonghang Xu, Jiannan Li, Lin Liu
    Cardiovascular Diabetology.2024;[Epub]     CrossRef
  • Triglyceride-glucose index predicts type 2 diabetes mellitus more effectively than oral glucose tolerance test-derived insulin sensitivity and secretion markers
    Min Jin Lee, Ji Hyun Bae, Ah Reum Khang, Dongwon Yi, Mi Sook Yun, Yang Ho Kang
    Diabetes Research and Clinical Practice.2024; 210: 111640.     CrossRef
  • Prognostic value of triglyceride-glucose index for left ventricular remodeling in nondiabetic ST-elevation myocardial infarction patients
    Tolga Han Efe, Engin Algül
    Biomarkers in Medicine.2024; 18(6): 243.     CrossRef
  • Triglyceride-Glucose Index as Predictor for Hypertension, CHD and STROKE Risk among Non-Diabetic Patients: A NHANES Cross-Sectional Study 2001–2020
    Bisher Sawaf, Sarya Swed, Hidar Alibrahim, Haidara Bohsas, Tirth Dave, Mohamad Nour Nasif, Wael Hafez, Fatema Ali Asgar Tashrifwala, Yazan Khair Eldien Jabban, Safwan Al-Rassas, Heba haj Saleh, Abdul Rehman Zia Zaidi, Baraa Alghalyini, Shaymaa Abdelmaboud
    Journal of Epidemiology and Global Health.2024; 14(3): 1152.     CrossRef
  • An Increasing Triglyceride–Glucose Index Is Associated with a Pro-Inflammatory and Pro-Oxidant Phenotype
    Beverley Adams-Huet, Ishwarlal Jialal
    Journal of Clinical Medicine.2024; 13(13): 3941.     CrossRef
  • Inflammatory and Metabolic Predictors of Mortality in Pulmonary Thromboembolism: A Focus on the Triglyceride–Glucose Index and Pan-Immune Inflammation Value
    Murat Bilgin, Emre Akkaya, Recep Dokuyucu
    Journal of Clinical Medicine.2024; 13(19): 6008.     CrossRef
  • The role of the triglyceride-glucose index as a biomarker of cardio-metabolic syndromes
    Verena Gounden, Sridevi Devaraj, Ishwarlal Jialal
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Evaluation of the novel three lipid indices for predicting five- and ten-year incidence of cardiovascular disease: findings from Kerman coronary artery disease risk factors study (KERCADRS)
    Alireza Jafari, Hamid Najafipour, Mitra Shadkam, Sina Aminizadeh
    Lipids in Health and Disease.2023;[Epub]     CrossRef
Close layer
Diabetes, Obesity and Metabolism
The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018
Ji Cheol Bae, Lauren A. Beste, Kristina M. Utzschneider
Endocrinol Metab. 2022;37(3):455-465.   Published online June 21, 2022
DOI: https://doi.org/10.3803/EnM.2022.1434
  • 5,926 View
  • 154 Download
  • 15 Web of Science
  • 15 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We aimed to investigate the association of hepatic steatosis with liver fibrosis and to assess the interactive effects of hepatic steatosis and insulin resistance on liver fibrosis in a nationally representative sample of United States adults.
Methods
We conducted a cross-sectional analysis using data from National Health and Nutrition Examination Survey 2017 to 2018, which for the first time included transient elastography to assess liver stiffness and hepatic steatosis. We evaluated the association between hepatic steatosis (using controlled attenuation parameter [CAP]) and clinically significant liver fibrosis (defined as liver stiffness ≥7.5 kPa) using logistic regression with an interaction term for hepatic steatosis and insulin resistance (defined as homeostatic model assessment of insulin resistance ≥3.0).
Results
Among adults undergoing transient elastography (n=2,023), 45.9% had moderate or greater hepatic steatosis and 11.3% had clinically significant liver fibrosis. After adjustment for demographic and metabolic factors, the odds of significant liver fibrosis increased as CAP score rose (odds ratio, 1.35 per standard deviation increment; 95% confidence interval, 1.11 to 1.64). We detected a significant interaction effect between CAP score and insulin resistance on the probability of significant liver fibrosis (P=0.016 for interaction). The probability of significant liver fibrosis increased in the presence of insulin resistance with increasing CAP score, while those without insulin resistance had low probability of significant liver fibrosis, even with high CAP scores.
Conclusion
Individuals with hepatic steatosis had higher odds of fibrosis when insulin resistance was present. Our findings emphasize the importance of the metabolic aspects of the disease on fibrosis risk and suggest a need to better identify patients with metabolic associated fatty liver disease.

Citations

Citations to this article as recorded by  
  • Association between the triglyceride-glucose index and liver fibrosis in adults with metabolism-related fatty liver disease in the United States: a cross-sectional study of NHANES 2017–2020
    Yuou Ying, Yuan Ji, Ruyi Ju, Jinhan Chen, Mingxian Chen
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Association of insulin resistance indicators with hepatic steatosis and fibrosis in patients with metabolic syndrome
    Tzu-chia Kuo, Yang-bor Lu, Chieh-lun Yang, Bin Wang, Lin-xin Chen, Ching-ping Su
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • No More NAFLD: The Term Is Now MASLD
    Ji Cheol Bae
    Endocrinology and Metabolism.2024; 39(1): 92.     CrossRef
  • Insulin Resistance/Sensitivity Measures as Screening Indicators of Metabolic-Associated Fatty Liver Disease and Liver Fibrosis
    Mohammad E. Khamseh, Mojtaba Malek, Soodeh Jahangiri, Sohrab Nobarani, Azita Hekmatdoost, Marieh Salavatizadeh, Samira Soltanieh, Haleh Chehrehgosha, Hoda Taheri, Zeinab Montazeri, Fereshteh Attaran, Faramarz Ismail-Beigi, Fariba Alaei-Shahmiri
    Digestive Diseases and Sciences.2024; 69(4): 1430.     CrossRef
  • The association of Neuromedin U levels and non-alcoholic fatty liver disease: A comparative analysis
    Murat Keskin, Sercan Avul, Aylin Beyaz, Nizameddin Koca
    Heliyon.2024; 10(5): e27291.     CrossRef
  • Oral Insulin Alleviates Liver Fibrosis and Reduces Liver Steatosis in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes: Results of Phase II Randomized, Placebo-controlled Feasibility Clinical Trial
    Yuval Ishay, Joel Neutel, Yotam Kolben, Ram Gelman, Orly Sneh Arbib, Oliver Lopez, Helena Katchman, Rizwana Mohseni, Miriam Kidron, Yaron Ilan
    Gastro Hep Advances.2024; 3(3): 417.     CrossRef
  • Comparative and Predictive Significance of Serum Leptin Levels in Non-alcoholic Fatty Liver Disease
    Mehwish Qamar, Abeer Fatima, Ambreen Tauseef, Muhammad I Yousufzai, Ibrahim Liaqat, Qanbar Naqvi
    Cureus.2024;[Epub]     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping
    Shahid Habib
    World Journal of Gastrointestinal Pathophysiology.2024;[Epub]     CrossRef
  • Appendicular skeletal muscle mass is associated with metabolic dysfunction-associated steatotic liver disease severity in young men: a cross-sectional and longitudinal study
    Jaejun Lee, Jinson So, Chang In Han, Hyun Yang, Pil Soo Sung, Si Hyun Bae, Do Seon Song
    Hepatology International.2024;[Epub]     CrossRef
  • Greater Severity of Steatosis Is Associated with a Higher Risk of Incident Diabetes: A Retrospective Longitudinal Study
    Ji Min Han, Jung Hwan Cho, Hye In Kim, Sunghwan Suh, Yu-Ji Lee, Jung Won Lee, Kwang Min Kim, Ji Cheol Bae
    Endocrinology and Metabolism.2023; 38(4): 418.     CrossRef
  • Hepatic T-cell senescence and exhaustion are implicated in the progression of fatty liver disease in patients with type 2 diabetes and mouse model with nonalcoholic steatohepatitis
    Byeong Chang Sim, Yea Eun Kang, Sun Kyoung You, Seong Eun Lee, Ha Thi Nga, Ho Yeop Lee, Thi Linh Nguyen, Ji Sun Moon, Jingwen Tian, Hyo Ju Jang, Jeong Eun Lee, Hyon-Seung Yi
    Cell Death & Disease.2023;[Epub]     CrossRef
  • Familial clustering of nonalcoholic fatty liver disease in first‐degree relatives of adults with lean nonalcoholic fatty liver disease
    Sorachat Niltwat, Chanin Limwongse, Natthinee Charatcharoenwitthaya, Duangkamon Bunditvorapoom, Wimolrak Bandidniyamanon, Phunchai Charatcharoenwitthaya
    Liver International.2023; 43(12): 2713.     CrossRef
  • Metabolic Score for Insulin Resistance Is Inversely Related to Incident Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
    Jun-Hyuk Lee, Yu-Jin Kwon, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
    Nutrients.2022; 14(15): 3039.     CrossRef
  • DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?
    Ji Cheol Bae
    Endocrinology and Metabolism.2022; 37(6): 858.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism
TOP